bosentan anhydrous has been researched along with Pulmonary Hypertension in 696 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (1.44) | 18.2507 |
| 2000's | 372 (53.45) | 29.6817 |
| 2010's | 292 (41.95) | 24.3611 |
| 2020's | 22 (3.16) | 2.80 |
| Authors | Studies |
|---|---|
| Aubert, JD; Juillerat-Jeanneret, L | 1 |
| Aisa, HA; Gong, X; He, Y; Jiang, H; Jiang, X; Li, J; Liu, Z; Shen, J; Shi, J; Suo, J; Tian, G; Wang, Y; Wang, Z; Wu, C; Wu, J; Xu, Y; Xu, Z; Yang, R; Yang, X; Zhang, R; Zhang, X; Zhu, W; Zou, X | 1 |
| Chen, J; Chen, Y; Li, F; Li, J; Luo, J; Luo, P | 1 |
| Chen, D; Chen, Y; Du, G; Fang, L; Niu, Z; Yuan, T; Zhang, H | 1 |
| Jia, JJ; Li, LX; Li, M; Wei, B; Yang, M | 1 |
| Alotaibi, M; Fernandes, TM; Hoang, HB; Kim, NH; Lombardi, S; Papamatheakis, DG; Poch, DS; Rodriguez, C; Wu, S; Yang, JZ | 1 |
| Ceriani, F; Cosentino, M; De Ponti, R; Ferrari, M; Imporzani, A; Lattanzio, M; Marino, F; Martini, S | 1 |
| Gorbachevsky, SV; Shmalts, AA | 2 |
| Ekhlasi, M; Majd, ZK; Peiravian, F; Sheikhi, S; Yousefi, N | 1 |
| Kuno, T; Matsuzaki, Y; Shirasu, T; Sumitomo, N; Takagi, H; Watanabe, A; Watanabe, H; Watanabe, K; Yasuhara, J | 1 |
| Amann, U; Haug, U; Kollhorst, B | 1 |
| Dwivedi, J; Jain, P; Jain, S; Jaiswal, S; Kumawat, J; Panchal, J; Sharma, A; Sharma, S; Verma, K | 1 |
| Sakao, S; Tanabe, N; Tatsumi, K | 1 |
| Brutsche, MH; Hostettler, KE | 1 |
| Carratù, P; Dragonieri, S; Resta, O | 1 |
| Kelder, JC; Mager, JJ; Post, MC; Snijder, RJ; Ten Klooster, L; van Thor, MCJ | 1 |
| Geiger, R; Kiechl-Kohlendorfer, U; Michel, M; Podnar, T; Ralser, E; Schermer, E; Stock, K | 1 |
| Sakao, S | 1 |
| Antunes, D; Guimarães, T; Pinto, FJ; Plácido, R; Sousa, I | 1 |
| Idris, N; Jeremiasen, I; Moledina, S; Tran, PK; Tran-Lundmark, K | 1 |
| Abman, SH; Kinsella, JP; Mandell, E | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Aleevskaya, AM; Martynyuk, TV | 1 |
| Casademont, J; Castellví, I; Corominas, H; Fonollosa, V; Sarmiento, M; Simeón, CP | 1 |
| Gao, C; Liu, J; Wu, Y; Zhang, R; Zhao, M | 1 |
| Halank, M; Held, M; Igarashi, T; Kunihara, T; Nomura, R; Sata, F; Schäfers, HJ; Wilkens, H | 1 |
| Chen, C; Chen, J; Chen, T; Chen, Y; Liu, M; Zheng, B; Zheng, H | 1 |
| Bega, E; Carratù, P; Damiani, MF; Dragonieri, S; Resta, O; Scoditti, A; Scoditti, C | 1 |
| Großer, C; Hoenicka, M; Hofmann, HS; Lang, G; Lehle, K; Neu, R; Ried, M; Szöke, T | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Boehm, C; Celermajer, D; Cordina, R; Corte, T; Garsia, R; Lau, E; Moonen, A; Torzillo, P; Youssef, P | 1 |
| Baughman, RP; Shlobin, OA | 1 |
| Apostolopoulou, SC; Rammos, S; Vagenakis, G | 1 |
| Dombi, T; Jansa, P; Teal, S; Vizza, CD; Zhou, D | 1 |
| Balli, E; Buyukakilli, B; Gurgul, S; Hallioglu, O; Karpuz, D; Ozeren, M; Tasdelen, B | 1 |
| Cancrini, C; D'Argenio, P; Diociaiuti, A; El Hachem, M; Iughetti, L; Onnis, G; Zangari, P | 1 |
| Alehan, D; Aykan, HH; Aypar, E; Ertugrul, İ; Karagöz, T | 1 |
| Gemma, A; Hino, M; Tanaka, Y | 1 |
| Apitz, C; Schranz, D | 1 |
| Bortoncello, LC; Cerski, CTS; Cheinquer, H; de Araujo, A; Gazzana, MB; Lopes, AB; Mantovani, A | 1 |
| Coghlan, C; Coghlan, JG; Dawson, A; Reddecliffe, S; Schreiber, BE | 1 |
| Alfraidi, H; Bshouty, Z; Qanash, S | 1 |
| Botella, A; Moniz, P; Rei, D; Rodrigues, J | 1 |
| Gong, SG; He, J; Jiang, R; Liu, JM; Pudasaini, B; Wang, L; Wu, WH; Yuan, P; Zhang, R; Zhao, QH; Zhou, CC | 1 |
| Rigatelli, G; Zuin, M | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Beghetti, M; Broberg, CS; Budts, W; D'Alto, M; Diller, GP; Dimopoulos, K; Gatzoulis, MA; Giannakoulas, G; Gu, H; Opotowsky, AR; Swan, L; Veldtman, G | 1 |
| Castel, MÁ; Farrero, M; García-Álvarez, A; Ivey-Miranda, JB; Perez-Villa, F; Rios, J; Santiago-Vacas, E | 1 |
| Emoto, N; Hirata, KI; Horibata, S; Kumagai, S; Miyagawa, K; Nakayama, K; Suzuki, Y; Tsuji, G; Uemura, Y; Yorifuji, K | 1 |
| Beaussier, M; Boucau, C; Cosserat, J; Denet, C; Mascitti, P; Montandrau, O; Philip, I | 1 |
| Chen, J; Liu, J; Qian, X; Tang, W; Xie, T; You, R; Zeng, F; Zhang, Y | 1 |
| Kuang, HY; Li, Q; Lu, TW; Wu, YH; Yi, QJ | 1 |
| Kim, SH; Lee, GJ; Li, W; Park, BM; Yu, L | 1 |
| Bouras, G; Cleman, MW; Deftereos, S; Giannopoulos, G; Kaoukis, A; Panagopoulou, V; Papoutsidakis, N; Raisakis, K; Stefanadis, C | 1 |
| El-Kersh, K; Fraig, M; Perez, RL; Smith, JS | 1 |
| Dai, HL; Guang, XF; Lu, YB; Xiao, ZC; Zhang, M; Zhang, WH | 1 |
| Feinstein, JA; Ivy, DD; Maxey, DM; Ogawa, MT | 1 |
| Antonova, OIu; Arkhipova, OA; Chazova, IE; Kobal', EA; Martyniuk, TV; Masenko, VP; Rvacheva, AV; Zykov, KA | 1 |
| Channick, RN | 1 |
| Behr, J; Jungck, D; Knobloch, J; Koch, A; Konradi, J; Lin, Y; Stoelben, E; Strauch, J | 1 |
| Dingemanse, J; Donazzolo, Y; Gutierrez, MM; Nicolas, LB | 1 |
| Avdeev, SN; Chuchalin, AG; Nekliudova, GV; tsareva, NA | 1 |
| Bendjilali, N; De Marco, T; Halladay, J; Hsueh, WC; Khojasteh, C; Kobashigawa, EA; Kroetz, DL; Le, H; Markova, SM; McGlothlin, D; Mefford, J; Rettie, AE; Schwartz, JB; Sodhi, J; Witte, JS; Wu, AH; Zhang, C | 1 |
| Fujimi, K; Fukuda, Y; Hiratsuka, M; Iwasaki, A; Miura, S; Nishikawa, H; Saku, K; Shiraishi, T; Yanagisawa, J; Yano, M | 1 |
| Gaine, SP; Murphy, DM; Murphy, DT; Murray, JG | 1 |
| Lee, JS; Lee, SD; Oh, YM; Park, DA; Park, J; Song, JH | 1 |
| Budts, W; De Meester, P; Delcroix, M; Gabriels, C; Jansen, K; Moons, P; Van De Bruaene, A; Voigt, JU | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Belperio, JA; Fishbein, MC; Lynch, JP; Saggar, R | 1 |
| Cannon, JE; Pepke-Zaba, J | 1 |
| Bresser, P; Kloek, JJ; Marcus, JT; Reesink, HJ; Surie, S; van der Plas, MN; Vonk-Noordegraaf, A | 1 |
| Bonilla-Palomas, JL; Gámez-López, AL; López-Ibáñez, MC; Moreno-Conde, M; Villar-Ráez, A | 1 |
| Aoyagi, K; Kawakami, A; Kawashiri, SY; Terada, K; Ueki, Y; Yamasaki, S | 1 |
| Steinhorn, RH | 1 |
| Cam, H; Dag, MS; Davutoglu, V; Durmus, E; Kivrak, T; Sari, I; Tigen, K | 1 |
| Deiros, L; Del Cerro, MJ; Gutierrez-Larraya, F; Herrero, A; Roldan, T; Romero, JA | 1 |
| Baughman, RP; Cordova, FC; Culver, DA; Engel, PJ; Gibson, KF; Lower, EE; Padilla, M | 1 |
| Hoenicka, M; Hofmann, HS; Liebold, A; Neu, R; Potzger, T; Ried, M; Sziklavari, Z; Szöke, T | 1 |
| Watkins, PB | 1 |
| Bernazzali, S; Caputo, M; Jelic, S; Maccherini, M; Mondillo, S; Padeletti, M; Tsioulpas, C; Zacà, V | 1 |
| Lee, YH; Song, GG | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Romaniello, A; Rosato, E; Salsano, F; Viola, G | 1 |
| Bartelds, B; Berger, RM; Douwes, JM; Hillege, HL; Ploegstra, MJ; Roofthooft, MT; Van Loon, RL | 1 |
| Deng, XX; Li, YP; Liu, M; Peng, T; Shang, XK; Tao, L; Zhang, GC; Zhou, HM | 1 |
| Al-Hiti, H; Galiè, N; Hoeper, MM; Jansa, P; Kusic-Pajic, A; Lemarié, JC; Meyer, GM; Rubin, LJ; Simonneau, G | 1 |
| Cingoz, F; Kurkluoglu, M; Sahin, MA; Tavlasoglu, M | 1 |
| Bortolamiol, C; Bossu, A; Clozel, M; Hess, P; Iglarz, M; Rey, M; Wanner, D | 1 |
| Ceribasi, AO; Demir, T; Dokuyucu, R; Kaplan, DS; Kisacik, B; Koc, I; Onat, AM; Orkmez, M; Pehlivan, Y; Taysi, S; Turkbeyler, IH; Tutar, E | 1 |
| Hu, L; Tan, LH; Ye, J | 1 |
| Bergot, E; Bouvaist, H; Bulifon, S; Cottin, V; Dauphin, C; Humbert, M; Jaïs, X; Macari, EA; Montani, D; Picard, F; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Kaneko, T; Saji, T; Sato, K; Sugi, K; Takahashi, K | 1 |
| Adachi, S; Hirashiki, A; Kondo, T; Matsubara, H; Miyaji, K; Murohara, T; Nakaguro, M; Ogawa, A; Yokoi, T | 1 |
| Tsareva, NA | 1 |
| Adachi, S; Hirashiki, A; Kondo, T; Kono, Y; Morimoto, R; Murohara, T; Nakano, Y; Okumura, T; Shimazu, S; Shimizu, S; Takeshita, K; Yamada, S | 1 |
| Benza, RL; Dhaun, N; Hwang, LJ; Liu, X; Naeije, R; Teal, S; Vachiery, JL; Webb, DJ | 1 |
| Guo, L; Liu, YJ; Xie, ZL | 1 |
| Bogaard, HJ; Botros, L; Van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Kario, K; Nishikawa-Takahashi, M; Ueno, S | 1 |
| Watanabe, H | 1 |
| Fukumoto, Y | 1 |
| Fontoura, D; Leite, S; Leite-Moreira, AF; Lourenço, AP; Mendes-Ferreira, P; Oliveira-Pinto, J; Tavares-Silva, M; Vasques-Nóvoa, F | 1 |
| Akita, C; Hirono, K; Ichida, F; Ishida, K; Kohno, H; Nakamura, T; Ozawa, S; Taguchi, M; Yoshimura, N | 1 |
| Morrell, NW; Pepke-Zaba, J; Sheares, K; Soon, E; Southwood, M | 1 |
| Fraidenburg, DR; Guo, Q; Huang, JA | 1 |
| Cebotari, S; Hoeper, MM; Madani, MM; Meyer, B; Nakanishi, N; Rubin, LJ | 1 |
| Babalis, D; Birring, SS; Corris, PA; Corte, TJ; Dimopoulos, K; Elliot, CA; Foley, C; Gatzoulis, MA; Howard, L; Keir, GJ; Maher, TM; Marino, P; O'Reilly, K; Parfitt, L; Renzoni, EA; Spencer, L; Wells, AU; Wort, SJ; Yanez-Lopez, M | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Amuro, H; Ito, T; Nishizawa, T; Nomura, S; Ozaki, Y; Son, Y; Tamaki, T; Tanaka, A | 1 |
| Carbone, RG; Nathan, SD | 1 |
| Glukhova, SI; Iudkina, NN; Kurmukov, IA; Nasonov, EL; Nikolaeva, EV; Volkov, AV | 1 |
| Fukuda, K; Funauchi, M; Hatano, M; Kuwana, M; Nakanishi, N; Saito, T; Saji, T; Sasayama, S; Sata, M; Taniguchi, M; Yamada, H; Yoshioka, K | 1 |
| Chen, Y; Feng, Y; He, J; Ren, Y | 1 |
| Davenport, AP; Maguire, JJ | 2 |
| Corkill, MM; Ghosh, SK; Hart, HH; Ng, KP | 1 |
| Güllülü, S; Sağ, S; Yeşilbursa, D | 1 |
| Buyukakilli, B; Citirik, D; Gurgul, S; Hallioglu, O; Ozeren, M; Tasdelen, B | 1 |
| Başer, HD; Cengel, A; Taçoy, G; Türkoğlu, S | 1 |
| He, F; Ren, R; Xiao, X | 1 |
| Gao, C; Li, B; Shang, L; Sheng, W; Yao, M; Ye, W | 1 |
| Bouillon, T; Flesch, G; Quinn, D; Renard, D; Zhou, P | 1 |
| Dingemanse, J; Krähenbühl, S; Sidharta, PN | 1 |
| Fujino, T; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Minatsuki, S; Muraoka, H; Nagai, R; Ono, M; Yao, A | 1 |
| Kinoshita, H; Yoshifuji, H | 1 |
| Ewald, GA; Garcia-Cortes, R; LaRue, SJ; Nassif, ME; Rasalingham, R; Ravichandran, A; Ray, S; Schilling, JD; Silvestry, SC; Vader, JM; Wang, IW | 1 |
| Park, IS | 1 |
| Yao, A | 1 |
| Aversa, M; Granton, J; Porter, S | 1 |
| Glukhova, SI; Kurmukov, IA; Nikolaeva, EV; Volkov, AV; Yudkina, NN | 1 |
| Bull, DA; Hatton, N; Ryan, JJ; Suksaranjit, P; Wilson, BD | 1 |
| Feng, Y; Ling, Y; Mei, F; Wang, Y | 1 |
| Fujita, J; Fukuda, K; Kataoka, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y; Yamamoto, T | 1 |
| Albini, A; Bacchi Reggiani, ML; Bachetti, C; Dardi, F; Galiè, N; Gotti, E; Manes, A; Mazzanti, G; Monti, E; Palazzini, M; Rinaldi, A | 1 |
| Avcu, F; Doganci, S; Erol, G; Kadan, M; Ozgurtas, T; Ozkan, G; Yesildal, F; Yildirim, V | 1 |
| Hatano, M; Imamura, T; Kinugawa, K; Komuro, I; Maki, H; Muraoka, H; Yao, A | 1 |
| Al Hiti, H; Channick, RN; Ghofrani, HA; Hoeper, MM; Lemarié, JC; McLaughlin, V; Meyer, G; Naeije, R; Packer, M; Souza, R; Tapson, VF; Tolson, J | 1 |
| Cocco, N; Madonna, R | 1 |
| di Serio, F; Iannone, F; Lapadula, G; Nivuori, M; Praino, E; Rotondo, C | 1 |
| Bauer, Y; Bortolamiol, C; Cattaneo, C; Clozel, M; Delahaye, S; Freti, D; Hadana, H; Hess, P; Iglarz, M; Landskroner, K; Nayler, O; Renault, B; Rey, M; Schläpfer, M; Steiner, P; Studer, R; Vercauteren, M; Vezzali, E; Wanner, D; Weber, E; Whitby, BR | 1 |
| Rubin, LJ; Vachiery, JL | 1 |
| Braun, J; Kleid, DM; Masarwa, R; Schulz, A; Shamriz, O; Stepensky, P; Weintraub, M; Zilkha, A | 1 |
| Chabanne, C; Cordier, JF; Cottin, V; Delaval, P; Girard, A; Jouneau, S; Khouatra, C; Lannes, M; Traclet, J; Turquier, S | 1 |
| Ando, K; Hoshika, Y; Ienaga, H; Kimura, T; Kuraishi, H; Morio, Y; Nagaoka, T; Takahashi, K; Tsutsumi, T | 1 |
| Kornacewicz-Jach, Z; Peregud-Pogorzelska, M | 1 |
| Berger, JT; Grant, EK | 1 |
| Burhenne, J; Enderle, Y; Friedrich, J; Grünig, E; Haefeli, WE; Meid, AD; Wilkens, H | 1 |
| Avdeev, SN | 1 |
| Hakamata, A; Inui, N; Irisawa, H; Miyakawa, S; Odagiri, K; Takeuchi, K; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Fan, R; Fan, Y; Ji, R; Penny, DJ; Varghese, NP; Wang, G; Zou, W | 1 |
| Lejnieks, A; Lesina, K; Rudzitis, A; Sablinskis, K; Skride, A | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Azuma, H; Kajihama, A; Kajino, H; Kamiyama, N; Maeda, J; Nakau, K; Oka, H; Sugimoto, M; Tasaki, Y; Yamagishi, H | 1 |
| Srinivas, NR | 1 |
| Dingemanse, J; Géhin, M; Sidharta, PN | 1 |
| Birk, E; Bruckheimer, E; Dagan, T; Kadmon, G; Schiller, O; Schonfeld, T | 1 |
| Igarashi, A; Inoue, S; Ishii, T; Tsutani, K; Watanabe, H | 1 |
| Jachowicz, R; Krupa, A; Majda, D; Mozgawa, W; Szlęk, J | 1 |
| Athalye-Jape, GK; More, K; Patole, SK; Rao, SC | 1 |
| Channick, R; Jais, X; Pepke-Zaba, J | 1 |
| Bae Lee, J; Kim, H; Lee, BR; Park, JH; Son, JW; Yang, DH; Yoo, BS | 1 |
| Akagi, S; Akagi, T; Ejiri, K; Ito, H; Nakagawa, K; Nakamura, K; Sarashina, T; Takaya, Y | 1 |
| Ammer, M; Ebner, CH; Eichinger, J; Grander, W; Herold, M; Koller, B; Pretsch, I; Schwaiger, J; Steringer-Mascherbauer, R; Ulmer, H; Weber, T | 1 |
| Blok, IM; Bouma, BJ; Mulder, BJM; van Dijk, APJ; van Riel, ACMJ | 1 |
| Beghetti, M; Dingemanse, J; Géhin, M; Krause, A; Kusic-Pajic, A; Zisowsky, J | 1 |
| Chai, Y; Dong, L; Fang, L; Han, X; Li, S; Liu, L; Niu, M; Qu, S; Yang, X; Yu, Y; Zhang, Y | 1 |
| Beghetti, M; Berger, RMF; Bonnet, D; Cornelisse, P; Gehin, M; Grill, S; Ivy, D; Kusic-Pajic, A | 1 |
| Angus, JA; Hughes, RJA; Soeding, PF; Wright, CE | 1 |
| Howard, LS; Price, LC | 1 |
| Ewert, R; Kirch, W; Opitz, CF; Pittrow, D | 1 |
| Dhaun, N; Webb, DJ | 1 |
| Al-Hiti, H; Chiossi, E; Galiè, N; Hoeper, M; Jansa, P; Kusic-Pajic, A; Meyer, G; Rubin, Lj; Simonneau, G | 1 |
| Akagi, S; Dan, K; Fujimoto, Y; Hisamatsu, K; Ikeda, E; Matsubara, H; Miyaji, K; Munemasa, M; Ohe, T; Tokunaga, N | 1 |
| Gewitz, M; Krishnan, S; Krishnan, U | 1 |
| Heresi, GA; Minai, OA | 1 |
| Arzt, M; Blumberg, FC; Budweiser, S; Luchner, A; Pfeifer, M; Schroll, S; Sebah, D; Stoelcker, B | 1 |
| Coghlan, G; Kabunga, P | 1 |
| Langevitz, P; Shalev, L; Zandman-Goddard, G | 1 |
| Dimitroula, H; Dimitroulas, T; Giannakoulas, G; Karvounis, H; Settas, L | 1 |
| Bouros, D; Steiropoulos, P; Trakada, G | 1 |
| Gabbay, E; Keogh, AM; McNeil, KD; Strange, G; Williams, TJ; Wlodarczyk, J | 1 |
| Hoeper, MM | 5 |
| Das, C; Doughty, N; Gin-Sing, W; Langley, J; McKenna, SP; Meads, DM; Pepke-Zaba, J | 1 |
| Mathier, MA | 1 |
| Ikeda, T; Ishikawa, S; Kobayashi, K; Takeyama, H; Tokuda, Y; Wakabayashi, K; Yano, S | 1 |
| Badagliacca, R; Benedetti, G; Crescenzi, E; Fedele, F; Ferrante, F; Letizia, C; Nona, A; Petramala, L; Poscia, R; Sciomer, S; Vizza, CD; Zepponi, E | 1 |
| Camara, B; Degano, B; Humbert, M; Jaïs, X; Le Pavec, J; Savale, L; Simonneau, G; Sitbon, O; Yaïci, A | 1 |
| Badesch, DB; Despain, DJ; Dufton, C; Frost, AE; Galie, N; Gerber, MJ; McGoon, MD; McLaughlin, VV; Olschewski, H; Oudiz, RJ; Rubin, LJ | 1 |
| Stähler, G | 1 |
| Ewert, R; Gläser, S; Opitz, CF; Schäper, C | 1 |
| Distler, O; Tamborrini, G | 1 |
| Dimopoulos, K; Gatzoulis, MA; Giannakoulas, G; Wort, SJ | 1 |
| Sitbon, O | 2 |
| Broomé, M; Frenckner, B; Lindström, M; Radell, P | 1 |
| King, TE | 1 |
| Haworth, SG; Hislop, AA | 1 |
| Dimopoulos, K; Gatzoulis, MA; Giannakoulas, G | 1 |
| Bresser, P; Duffels, MG; Mulder, BJ; Ponse, D; van der Plas, MN | 1 |
| Funauchi, M; Hino, S; Kinoshita, K; Kishimoto, K; Nagare, Y; Shimazu, H; Yano, T | 1 |
| Berger, RM; Bouma, BJ; Bresser, P; de Bruin-Bon, RH; Duffels, MG; Hardziyenka, M; Hoendermis, ES; Mulder, BJ; Surie, S; Tan, HL; van Dijk, AP | 1 |
| Kishi, T; Sunagawa, K | 1 |
| Emoto, N; Hirata, K; Iwasa, N; Kato, H; Kawai, H; Kuroda, Y; Matsuo, N; Miyagawa, K; Ohnishi, T; Yoshida, A | 1 |
| Jiang, X; Jing, ZC; Ma, CR; Pan, L; Wang, Y; Wu, Y; Xu, XQ; Yang, YJ | 1 |
| Agard, C; Haloun, A; Hamidou, MA | 1 |
| D'Armini, AM; Delcroix, M; Ghofrani, HA; Hoeper, MM; Jaïs, X; Jansa, P; Lang, IM; Mayer, E; Morganti, A; Pepke-Zaba, J; Perchenet, L; Rubin, LJ; Simonneau, G; Torbicki, A | 1 |
| Ahmad, S; Barnett, CF; Barnett, SD; Bonura, EJ; Girgis, RE; Hassoun, PM; Moller, DR; Nathan, SD; Osei, K; Shlobin, OA; Zaiman, AL | 1 |
| De Wolf, D | 1 |
| Li, D; Matuschak, GM; Nayak, RP | 1 |
| Faruqi, S; Fathi, H; Morice, AH | 1 |
| Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
| Argyropoulou, P; Boutou, AK; Pitsiou, G; Stanopoulos, I | 1 |
| Jardim, C; Souza, R | 1 |
| Canu, P; Cordier, JF; Cottin, V; Khouatra, C; Lazor, R | 1 |
| Preston, IR; Steiner, MK | 1 |
| Konishi, K; Kuriyama, T; Maruoka, M; Nakamura, M; Shigeta, A; Shinohara, M; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Toyama, S; Yasuda, T | 1 |
| Cella, G; Cozzi, F; Fareed, J; Iqbal, O; Marotta, H; Saggiorato, G; Tona, F; Vianello, F | 1 |
| Caruso, C; Giovannetti, A; Pierdominici, M; Romano, A; Rosato, E; Salsano, F | 1 |
| Nitschmann, S; Reichenberger, F; Seeger, W | 1 |
| He, JG; Tan, XY | 1 |
| Cassandro, R; Confalonieri, M; Harari, S; Kodric, M; Piattella, M; Potena, A; Scarda, A; Scarduelli, C; Vassallo, FG | 1 |
| Beghetti, M; Galiè, N | 1 |
| Ankersmit, HJ; Bonderman, D; Hoetzenecker, K; Hoetzenecker, W; Klepetko, W; Lang, IM; Seitelberger, R | 1 |
| Dwyer, N; Jones, G; Kilpatrick, D | 1 |
| Dias, B; Fine, N; Mehta, S; Shoemaker, G | 1 |
| Boonstra, A; Jacobs, W; Marcus, JT; Postmus, PE; Vonk-Noordegraaf, A | 1 |
| Bracciale, P; Grazia D'Agostino, A; Valerio, G | 1 |
| Cacoub, P; Langleben, D | 1 |
| Fujimoto, M; Hamaguchi, Y; Hasegawa, M; Matsushita, T; Takehara, K | 1 |
| Beghetti, M | 2 |
| Hayashida, A; Hino, T; Kawamoto, T; Neishi, Y; Obase, K; Okahashi, N; Okura, H; Wada, N; Watanabe, N; Yoshida, K | 1 |
| Hadi, AM; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Versteilen, AM; Vonk-Noordegraaf, A | 1 |
| Berger, RM; Bouma, BJ; Bresser, P; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Nieuwkerk, PT; van Dijk, AP; van Loon, RL; Vis, JC | 1 |
| Doherty, DR; Eipe, N; Lai, L | 1 |
| Kostrubiec, M; Pedowska-Włoszek, J; Pruszczyk, P | 1 |
| Beghetti, M; Berger, RM; Chiossi, E; Galiè, N; Gatzoulis, MA; Granton, J; Landzberg, M; Lauer, A | 1 |
| Drinovec, I; Jazbec, SS; Ledinek, AH; Rot, U | 1 |
| Barst, RJ; Beardsworth, A; Brundage, BH; Chan, M; Frumkin, L; Galiè, N; Ghofrani, HA; Oudiz, RJ; Safdar, Z; Shapiro, S; Simonneau, G; White, RJ | 1 |
| Arita, Y; Fujio, Y; Higuchi, K; Hiramoto, Y; Kuroda, T; Nakaoka, Y; Sakata, Y; Shioyama, W; Yamauchi-Takihara, K | 1 |
| Coghlan, G; Humbert, M; McLaughlin, V; Nash, P; Steen, V | 1 |
| Guillevin, L | 1 |
| Kanno, T; Kyozuka, H; Nishida, T; Ohira, H; Suzuki, E | 1 |
| Mucke, HA | 1 |
| Dessy, H; Dewolf, D; Gewillig, M; Mertens, L; Moons, P; Ottenkamp, J; Ovaert, C; Thijs, D | 1 |
| Choksuchat, D; Nakwan, N; Saksawad, R; Thammachote, P | 1 |
| Safdar, Z | 1 |
| Csete, M; Heffron, T; Knowles, D; Lawrence, EC; Tapper, EB | 1 |
| Dranitsaris, G; Mehta, S | 1 |
| Boutou, AK; Kioumis, I; Nakou, C; Pitsiou, GG; Spyratos, D; Stanopoulos, I | 1 |
| Baldi, S; D'Angelo, S; Naclerio, C; Scarpato, S; Tagliamonte, G | 1 |
| Franco-Jaramillo, G; Londoño-Villegas, A; Ortega-Jaramillo, J; Ortiz-Uribe, JC; Vallejo-García, FJ | 1 |
| Bresser, P; Fedullo, PF; Kloek, JJ; Reesink, HJ; Surie, S; Tan, HL; Tepaske, R | 1 |
| Coghlan, JG; Valerio, CJ | 1 |
| Beghetti, M; Tissot, C | 1 |
| Ghofrani, HA | 1 |
| Bach, D; Dingemanse, J; Doelberg, M; Galiè, N; Gruenig, E; Meyer, FJ; Michelakis, E; Vachiéry, JL; Vizza, CD | 1 |
| Coles, WA; Gladwin, MT; Kato, GJ; Machado, RF; Minniti, CP; Sachdev, V | 1 |
| Dhillon, S; Keating, GM | 1 |
| Brockmeyer, DL; Day, RW; Feola, GP | 1 |
| Wimmersberger, Y; Zuercher, D | 1 |
| Barton, P; Chen, YF; Fry-Smith, A; Gibbs, JS; Hyde, C; Jowett, S; Malottki, K; Moore, D; Pepke-Zaba, J; Roberts, J | 1 |
| Dorfmuller, P; Humbert, M; Jaïs, X; Montani, D; Simonneau, G; Sitbon, O | 1 |
| David, S; Feldman, D; Ghanbari, H; Saba, S | 1 |
| Arzt, M; Blumberg, F; Nüchterlein, M; Pfeifer, M; Schroll, S; Sebah, D | 1 |
| Confalonieri, M; Kodric, M; Longo, C; Vassallo, FG | 1 |
| Acar, P; Barst, RJ; Beghetti, M; Berger, RM; Bonnet, D; Dingemanse, J; Fraisse, A; Galiè, N; Haworth, SG; Ivy, DD; Jais, X; Kusic-Pajic, A; Morganti, A; Schulze-Neick, I | 1 |
| Dalton, B; Gabbay, E; Keogh, A; McNeil, K; Proudman, S; Strange, G; Weintraub, RG; Williams, TJ; Wlodarczyk, J | 1 |
| Achouh, L; Humbert, M; Jais, X; Launay, D; Le Pavec, J; Parent, F; Savale, L; Simonneau, G; Sitbon, O; Tchérakian, C; Yaïci, A | 1 |
| Ross, AF; Ueda, K | 1 |
| Bambara, LM; Biasi, D; Caramaschi, P; Mahamid, H | 1 |
| Carter, NJ; Keating, GM | 1 |
| Borst, MM; Bruckner, T; Droste, AS; Filusch, A; Katus, HA; Meyer, FJ; Rohde, D; Voelkers, M | 1 |
| Cai, XM; Ji, G; Liu, JF; Su, ZK; Xu, ZM; Zhu, LM | 1 |
| Cheng, XS; Dalton, BS; Gu, H; Jing, ZC; Pan, X; Shen, JY; Strange, G; Wang, Y; Xiang, MX; Yang, YJ; Yang, ZK; Yao, H; Zhang, ZL; Zhao, DB; Zhou, DX; Zhu, XY | 1 |
| Park, MH; Rubin, LJ | 1 |
| Corris, PA; Langleben, D | 1 |
| Acar, P | 1 |
| Dalton, B; Gabbay, E; Keogh, A; Steele, P; Stewart, S; Strange, G; Wlodarczyk, J | 1 |
| Saxena, S; Spangler, ML | 1 |
| Agnelli, G; Becattini, C; Busti, C; Gennarini, S; Manina, G | 1 |
| Ataga, KI; Barst, RJ; Benza, RL; Castro, O; Gladwin, MT; Hildesheim, M; Machado, RF; Mubarak, KK; Naeije, R; Sood, N; Swerdlow, PS | 1 |
| Humbert, M; Montani, D | 1 |
| Humbert, M; Jais, X; Sanchez, O; Simonneau, G; Sitbon, O | 1 |
| Hunsche, E; Lefebvre, MC | 1 |
| Ishizawar, D; Mathier, MA | 1 |
| Backman, ES; Farber, HW; Hardy, H | 1 |
| de Boer, MA; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Castel, A; Farrero, M; Perez-Villa, F; Roig, E; Sionis, A | 1 |
| Janda, S; Quon, BS; Swiston, J | 1 |
| Benza, RL; Channick, RN; McLaughlin, VV; Olschewski, H; Robbins, IM; Rubenfire, M; Rubin, LJ; Seeger, W; Tapson, VF; Voswinckel, R | 1 |
| Hirono, K; Ichida, F; Miyawaki, T; Nakamura, T; Taguchi, M; Watanabe, K; Yoshimura, N | 1 |
| Dunnington, GH; Johri, S; Vnencak-Jones, CL | 1 |
| Du, J; He, B; Jin, H; Li, X; Lin, G; Tang, C; Zhang, F | 1 |
| Boonstra, A; Brand, M; Jacobs, W; Postmus, PE; Rosenberg, DM; Schaaf, B; Vonk Noordegraaf, A | 1 |
| Dupuis, J; Jiang, BH; Shi, Y; Tardif, JC | 1 |
| Cordier, JF; Cottin, V; Etienne-Mastroïanni, B; Humbert, M; Khouatra, C; Kiakouama, L | 1 |
| Angalakuditi, M; Bancroft, T; Beardsworth, A; Buysman, E; Edgell, E | 1 |
| Argiento, P; Calabrò, R; D'Alto, M; Gaio, G; Mélot, C; Naeije, R; Romeo, E; Russo, MG; Santoro, G; Sarubbi, B | 1 |
| Coghlan, JG; Denton, CP; Handler, CE; Kabunga, P; Smith, CJ; Valerio, CJ | 1 |
| Cachulo, Mdo C; Costa, GV; Leitão-Marques, AM; Lemos, CG; Providência, R; Silva, J | 1 |
| Borghese, F; Molinaro, I; Pisarri, S; Rosato, E; Rossi, C; Salsano, F | 1 |
| Antoniadou, M; Kosmas, A; Michaelidis, V; Serasli, E; Tsara, V | 1 |
| Bang, WD; Chang, HJ; Cho, SS; Jang, JY; Joung, B; Kim, JY; Oh, CM; Yu, HT | 1 |
| Bilan, VP; Jackson, EK; Jones, TJ; Petrusevska, G; Tofovic, SP | 1 |
| Akkoca Yıldız, O; Karabıyıkoğlu, G; Onen, ZP; Ozdemir Kumbasar, O; Sayın, T | 1 |
| Kähler, CM | 1 |
| Adamopoulos, S; Chaidaroglou, A; Degiannis, D; Georgiadou, P; Gkouziouta, A; Karabela, G; Karavolias, GK; Kariofillis, P; Sbarouni, E; Tsiapras, D; Voudris, V | 1 |
| Israël-Biet, D; Lerolle, U; Marié, E; Meyer, G; Sanchez, O; Wermert, D | 1 |
| Holzgrabe, U; Schmitz, J | 1 |
| Breitkreutz, J; Läer, S; Ramusovic, S | 1 |
| Barst, RJ; Brand, M; Ivy, DD; Lemarié, JC; Rosenberg, D; Rosenzweig, EB | 1 |
| Aihara, K; Akaike, M; Dagvasumberel, M; Hirata, Y; Iwase, T; Koshiba, K; Kusunose, K; Matsumoto, T; Niki, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yoshida, S | 1 |
| Gocho, K; Homma, S; Kusano, E; Ota, H; Sugino, K; Takai, Y | 1 |
| Argiento, P; Calabrò, R; Correra, A; D'Alto, M; Grimaldi, N; Romeo, E; Russo, MG; Santoro, G; Sarubbi, B; Scognamiglio, G | 1 |
| Brown, K; Dalton, B; Gabbay, E; Keogh, A; Kermeen, F; Kilpatrick, D; Kotlyar, E; Macdonald, P; Pidoux, A; Steele, P; Strange, G; Williams, T | 1 |
| Gatzoulis, MA; Giannakoulas, G | 1 |
| Adams, MR; Celermajer, DS; Ilsar, R; Kritharides, L; Levitt, J; Ng, MK | 1 |
| Chang, SA; Jang, SY; Kang, IS; Ki, CS; Kim, DK | 1 |
| Kumarasinghe, SP; Tong, PL | 1 |
| Dwyer, N; Kilpatrick, D | 1 |
| Foster, H; Haworth, SG; Hislop, AA; Moledina, S; Schulze-Neick, I | 1 |
| Derk, CT; Shetty, N | 1 |
| Barst, RJ; Beardsworth, A; Brundage, BH; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G; Sundin, DP | 1 |
| Clarke, B; Hadi, H; Hamid, T; Mahadevan, V | 1 |
| de Man, FS; Handoko, ML; Vonk-Noordegraaf, A | 1 |
| Arkhipova, OA; Ataullakhanova, DM; Chazova, IE; Danilov, NM; Lazutkina, VK; Martyniuk, TV; Samoĭlenko, LE; Stukalova, OV | 1 |
| Akita, C; Hashimoto, Y; Hirono, K; Horiuchi, I; Ichida, F; Kato, Y; Miyawaki, T; Nakamura, T; Nakayama, T; Saji, T; Taguchi, M; Yoshimura, N | 1 |
| Davie, N; Hall, SM; Haworth, SG; Klein, N | 1 |
| Dai, LZ; Jiang, X; Jing, ZC; Wang, GY; Wang, Y; Wu, BX; Yao, H; Yu, ZX | 1 |
| Fuchs, U; Gummert, JF; Hefke, T; Schulte-Eistrup, S; Schulz, U; Zittermann, A | 1 |
| Eriksson, C; Gustavsson, A; Kronvall, T; Tysk, C | 1 |
| Pope, J; Walker, KM | 1 |
| Humbert, M; Jaïs, X; Montani, D; Natali, D; O'Callaghan, DS; Parent, F; Savale, L; Simonneau, G; Sitbon, O; Yaïci, A | 1 |
| Audia, S; Berthier, S; Bonnotte, B; Leguy, V; Lorcerie, B; Roch, N; Samson, M | 1 |
| Choudhary, G; Harrington, EO; Klinger, JR; Martin, D; Troncales, F | 1 |
| Bauleo, C; Catapano, G; Formichi, B; Genovesi, D; Giuntini, C; Mannucci, F; Marini, C; Michelassi, C; Monti, S; Prediletto, R | 1 |
| Iwamoto, Y; Kawasaki, H; Senzaki, H; Taketazu, M; Tamai, A | 1 |
| Cleary, H; Edelman, K; López-Candales, A | 1 |
| Kaneko, H; Mimori, A; Takahashi, Y; Ueda, Y; Yamashita, H | 1 |
| Bilici, M; Guzeltas, A; Odemis, E; Özyılmaz, İ; Tanidir, IC | 1 |
| Dalton, B; Gabbay, E; Keogh, A; Strange, G | 1 |
| Cai, Y; Guo, F; Kuang, JL; Yan, CS; Ye, XQ; Zhang, XY | 1 |
| Alonso-Pulpón, L; Avellana, P; García-Cosío Carmena, MD; García-Pavía, P; Gómez-Bueno, M; Gutiérrez Landaluce, C; Pérez Pereira, E; Segovia, J; Sufrate, E | 1 |
| Andrews, JC; Kamath, PS; Krowka, MJ; Swanson, KL; Talwalkar, JA | 1 |
| Berger, RM; Bouma, BJ; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Mulder, P; van Dijk, AP; Vis, JC | 1 |
| Andreassen, AK; Gude, E; Solberg, OG; Ueland, T | 1 |
| Bouma, BJ; Budts, W; Celermajer, D; Cordina, R; Gatzoulis, MA; Mulder, BJ; Mullen, MP; Schuuring, MJ; Vis, JC | 1 |
| Hashida, Y; Nakayama, Y; Ohta, K; Saito, T; Shimizu, M; Takehara, K; Ueno, K; Yachie, A; Yokoyama, T | 1 |
| Argiento, P; Bossone, E; Calabrò, R; Correra, A; D'Alto, M; D'Andrea, A; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Scognamiglio, G; Vizza, CD | 1 |
| Cortijo, J; Gabarda, E; Guijarro, R; Juan, G; Martorell, M; Milara, J; Morcillo, EJ; Ortiz, JL | 1 |
| Hatano, M; Hirata, Y; Kinugawa, K; Nagai, R; Yao, A | 1 |
| Aizawa, Y; Ito, E; Maie, K; Ohno, Y; Sato, A; Tanabe, Y; Yoshida, T | 1 |
| Akamata, K; Asano, Y; Hatano, M; Ichimura, Y; Kawashima, T; Kinugawa, K; Miyazaki, M; Noda, S; Sato, S; Sugita, M; Sumida, H; Takahashi, T; Tamaki, Z; Taniguchi, T; Tomita, M; Toyama, T; Yao, A | 1 |
| French, B; Gabler, NB; Halpern, SD; Kawut, SM; Liu, Z; Palevsky, HI; Strom, BL; Taichman, DB | 1 |
| Clarke, B; Griffiths, L; Mahadevan, VS; Monfredi, O | 1 |
| Datar, SA; Fineman, JR; Oishi, P | 1 |
| Brasch, F; Bucher, B; Casaulta, C; Griese, M; Navarini, S; Pavlovic, M; Pfammatter, JP; Regamey, N | 1 |
| Imanishi, J; Miwa, Y; Shimizu, M; Takano, T | 1 |
| Aizawa, T; Hatano, M; Inaba, T; Kinugawa, K; Maki, H; Nagai, R; Shiga, T; Yamashita, T; Yao, A | 1 |
| Hamidi, SA; Jiang, YP; Lin, RZ; Lyubsky, S; Said, SI; Szema, AM | 1 |
| Celermajer, DS; Fowler, D; Garsia, R; Low, AJ; Manghani, MK; Torzillo, P; Young, I; Youssef, P | 1 |
| Benza, RL; Channick, RN; McLaughlin, VV; Olschewski, H; Robbins, IM; Rubin, LJ; Seeger, W; Tapson, VF; Voswinckel, R | 1 |
| Ismail, M; Mohamed, WA | 1 |
| Aoyagi, S; Honda, A; Imaizumi, T; Kodama, N; Koiwaya, H; Mizoguchi, M; Nitta, Y; Tahara, A; Tahara, N | 1 |
| Franklin, WJ; Parekh, DR; Safdar, Z | 1 |
| Aberer, E; Brodmann, M; Graninger, W; Hesse, C; Kovacs, G; Kqiku, X; Maier, R; Olschewski, H; Rubin, L; Scheidl, S; Tröster, N | 1 |
| Gatzoulis, MA | 1 |
| Humbert, M; Jaïs, X; Kemp, K; Montani, D; O'Callaghan, DS; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Caballero Eraso, C; Elías Hernández, T; Ferrer Galván, M; Jara Palomares, L; López Villalobos, JL; Otero Candelera, R | 1 |
| Daniels, CJ; Mueller, J; Smith, JS | 1 |
| Aoki, T; Fukumoto, Y; Miura, Y; Miyamichi-Yamamoto, S; Nochioka, K; Satoh, K; Shimokawa, H; Sugimura, K; Tatebe, S | 1 |
| Allard, M; Dufton, C; Gillies, H; Regnault, J; Venitz, J; Zack, J | 1 |
| Covarelli, C; Losito, A; Pittavini, L | 1 |
| Badagliacca, R; Fedele, F; Gambardella, C; Iacoboni, C; Letizia, C; Mancone, M; Marcon, S; Nona, A; Papa, S; Pezzuto, B; Poscia, R; Riccieri, V; Vizza, CD; Volterrani, M | 1 |
| Chatelus, E; Cinquetti, G; Gottenberg, JE; Javier, RM; Ronde-Oustau, C; Sibilia, J; Sordet, C | 1 |
| Huang, XM; Yu, YP | 1 |
| Hara, T; Ihara, K; Ikeda, K; Nagata, H; Yamamura, K | 1 |
| Couderc, LJ; Metivier, AC; Rivaud, E; Tcherakian, C; Zucman, D | 1 |
| Sirmagul, B; Yigitaslan, S | 1 |
| Adams, MR; Bailey, BP; Celermajer, DS; Ilsar, R; Iyer, N; Lau, EM | 1 |
| Brady, D; Calderbank, M; Ivy, DD; Rosenzweig, EB; Takatsuki, S; Zuckerman, W | 1 |
| Nishibu, A; Oyama, N; Sakai, E; Yamamoto, T | 1 |
| Lau, EM; McCaughan, GW; Torzillo, PJ | 1 |
| Allen, RP; Arneson, C; Badesch, DB; Frantz, RP; Frost, AE; Galiè, N; Keogh, AM; Kermeen, F; Laliberte, K; Shapiro, SM; Sigman, J; Tapson, VF; Torres, F | 1 |
| Dingemanse, J; Humbert, M; Jaïs, X; Le Pavec, J; Magnier, R; Montani, D; O'Callaghan, DS; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Athanassopoulos, GD; Demerouti, EA; Karatasakis, GT; Leontiadis, ED; Manginas, AN; Pavlides, GS | 1 |
| Barst, RJ; Beardsworth, A; Botros, FT; Brundage, BH; Chan, M; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G | 1 |
| Blenkhorn, F; Eisenberg, MJ; Fox, B; Hirsch, AM; Joyal, D; Langleben, D; Lesenko, L; Schlesinger, RD | 1 |
| Fedele, F; Pezzuto, B; Rubin, LJ; Vizza, CD | 1 |
| Rubin, LJ | 2 |
| Anthi, A; Armaganidis, A; Hamodraka, ES; Lekakis, J; Orfanos, SE; Tsangaris, I | 1 |
| Catrina, D; Coman, IM; Dima, L; Ghiorghiu, I; Ginghina, C; Giusca, S; Jurcut, R; Popescu, BA | 1 |
| Luo, N; Ryan, JJ | 1 |
| Aldashev, AA; Imanov, B; Isakova, J; Ishizaki, T; Kojonazarov, B; Sooronbaev, T; Sovkhozova, N | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Nagai, R; Ono, M; Shiga, T; Yao, A | 1 |
| Clozel, M; Gatfield, J; Mueller Grandjean, C; Nayler, O; Sasse, T | 1 |
| Aggarwal, S; Black, SM; Jonigk, D; Kumar, S; Rafikov, R; Rafikova, O; Schneider, F; Sharma, S; Tofovic, SP | 1 |
| Gerry Coghlan, J; Humbert, M; Khanna, D | 1 |
| Daniels, CJ | 1 |
| Galiè, N; Guazzi, M | 1 |
| D'Alto, M; Mahadevan, VS | 1 |
| McLaughlin, VV | 3 |
| Emoto, N; Fukuda, Y; Hirata, K; Kawai, H; Motoji, Y; Ryo, K; Tanaka, H | 1 |
| Berrevoet, F; Colle, I; De Pauw, M; Geerts, A; Raevens, S; Reyntjens, K; Rogiers, X; Troisi, RI; Van Vlierberghe, H; Verhelst, X | 1 |
| Celermajer, DS; Corte, TJ; Don, GW; Joseph, F | 1 |
| Held, M; Jany, BH | 1 |
| Cardarelli, S; Cozzi, F; Favaro, M; Pigatto, E; Punzi, L; Riato, L; Rizzo, M; Zanatta, E | 1 |
| Baptista, R; Castro, G; da Silva, AM; Monteiro, P; Providência, LA | 1 |
| Pereira, BN; Salvi, S | 1 |
| Dietrich, CG; Geier, A; Lammert, F | 1 |
| Schachna, L; Wigley, FM | 1 |
| Cabane, J; Humbert, M | 1 |
| Maloney, JP | 1 |
| Varga, J | 1 |
| Brimioulle, S; Kerbaul, F; Ketelslegers, JM; McEntee, K; Motte, S; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; van Beneden, R; Wauthy, P | 1 |
| Barst, R; Channick, R; Dujardin, K; Espinola-Zavaleta, N; Fourme, T; Frantz, R; Galiè, N; Hinderliter, AL; Kronenberg, A; Kurzyna, M; Leconte, I; Manes, A; Nagueh, SF; Pulido, T; Rainisio, M; Rocchi, G; Rubin, L; Simonneau, G; Torbicki, A | 1 |
| Barst, RJ; Bingaman, D; Dingemanse, J; Doran, A; Gaitonde, M; Ivy, D; Nguyen, N; Schmitt, K; van Giersbergen, PL; Widlitz, A | 1 |
| McCormack, D | 1 |
| Mayes, MD | 1 |
| Dupuis, J; Langleben, D; Michel, RP | 1 |
| Sharma, S | 1 |
| Badesch, DB; Channick, RN; Frost, A; Robbins, IM; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Nielsen-Kudsk, JE | 1 |
| Bekjarova, A; Gatzke, R; Hoeper, MM; Spiekerkoetter, E; Taha, N | 1 |
| Hey, JC; Scharf, SM | 1 |
| Brimioulle, S; Fesler, P; Kerbaul, F; Ketelslegers, JM; McEntee, K; Motte, S; Naeije, R; Rondelet, B; Van Beneden, R | 1 |
| Minushkina, LO; Sidorenko, BA; Zateĭshchikov, DA | 1 |
| Gorenflo, M; Ullmann, MV | 1 |
| Mehta, S | 1 |
| Highland, KB; Mazur, J; Simpson, KN; Strange, C | 1 |
| Clozel, M | 1 |
| Perry, CM; Prakash, A | 1 |
| Barazzone-Argiroffo, C; Beghetti, M; Nicod, L; Rimensberger, PC | 1 |
| Branzi, A; Galié, N; Manes, A | 1 |
| Wilkins, MR | 1 |
| Gaine, SP; O'Callaghan, D | 1 |
| Poon, M; Sulica, R | 1 |
| Hachulla, E | 1 |
| Bingaman, D; Claussen, L; Doran, A; Ivy, DD; Yetman, A | 1 |
| Budde, K; Dingemanse, J; Hocher, B; Liefeldt, L; Neumayer, HH; Rudolph, B; van Giersbergen, PL; Walde, T | 1 |
| Channick, R; Chin, K | 1 |
| Halank, M; Hoeffken, G; Miehlke, S; Schmeisser, A; Schulze, M; Strasser, RH | 1 |
| Bramhall, S; Clift, PF; Isaac, JL; Townend, JN | 1 |
| Kawut, SM; Palevsky, HI | 1 |
| Galié, N; Naeije, R; Peacock, A; Reeves, JT | 1 |
| Chahine, C; Cohen, H; Hui, A; Mukherji, R | 1 |
| Benticuaga Martínez, MN; Callejas Rubio, JL; de la Higuera Torres-Pujol, JM; Ortego Centeno, N | 1 |
| Fraisse, A; Habib, G | 1 |
| Balbir-Gurman, A; Braun-Moscovici, Y; Nahir, AM | 1 |
| Coghlan, JG; Hachulla, E | 1 |
| Cooper, DA; Delfraissy, JF; Fourme, T; Gressin, V; Humbert, M; Macdonald, PS; Opravil, M; Simonneau, G; Sitbon, O; Speich, R | 1 |
| Kunichika, H; Kunichika, N; Landsberg, JW; Rubin, LJ; Thistlethwaite, PA; Yu, Y; Yuan, JX | 1 |
| Gasser, S; Kuhn, M; Speich, R | 1 |
| Barst, RJ; Boonstra, A; Channick, RN; Galiè, N; Horn, EM; Humbert, M; Manes, A; Robbins, IM; Rubin, LJ; Simonneau, G | 1 |
| Frost, AE; Suleman, N | 1 |
| Humbert, M; Ioos, V; Jaïs, X; Montani, D; Simonneau, G; Sitbon, O | 1 |
| Yoshibayashi, M | 1 |
| Alber, H; Colleselli, D; Kähler, CM; Molnar, C; Vogel, W | 1 |
| Graziadei, IW; Hinterhuber, L; Jaschke, W; Kähler, CM; Vogel, W | 1 |
| Faulenbach, C; Golpon, H; Hoeper, MM; Niedermeyer, J; Welte, T; Winkler, J | 1 |
| Ahmadi-Simab, K; Gross, WL; Hellmisch, B; Lamprecht, P | 1 |
| Gerbes, AL; Gülberg, V; Kuntzen, C | 1 |
| Chin, KM; Kim, NH; Rubin, LJ | 1 |
| Dingemanse, J; Giersbergen, PL; Izumi, T; Kunieda, T; Kuriyama, T; Matsuzaki, M; Origasa, H; Sasayama, S; Shirato, K; Tanaka, S; Tomoike, H | 1 |
| Cheng, J; Liu, C | 1 |
| Humbert, M | 2 |
| Badesch, DB; Barst, RJ; Black, C; Galiè, N; McLaughlin, VV; Rainisio, M; Rubin, LJ; Simonneau, G; Sitbon, O | 1 |
| Halank, M; Hoeffken, G; Hoeper, MM; Marx, C; Niedermeyer, J; Schauer, J; Seyfarth, HJ; Winkler, J | 1 |
| Widmar, B | 1 |
| Banya, WA; Gibbs, JS; Gin-Sing, W; Mohiaddin, RH; Ng, LL; Nihoyannopoulos, P; Paul, GA; Pennell, DJ; Stefanidis, A; Strange, JW; Tunariu, N; Westwood, MA; Wilkins, MR | 1 |
| Apostolopoulou, SC; Cokkinos, DV; Manginas, A; Rammos, S | 2 |
| Antonaci, S; Giannelli, G; Iannone, F; Lapadula, G; Marinosci, F | 2 |
| Taéron, C | 1 |
| Shi, GY | 1 |
| Grau, RG; Jacobs, MR; Knox, KS; Snyder, MJ; Wilkes, DS | 1 |
| Champion, HC; Diette, GB; Girgis, RE; Johns, RA; Permutt, S; Sylvester, JT | 1 |
| Fruhwald, FM; Kjellström, B; Klein, W; Maier, R; Perthold, W; Wonisch, M | 1 |
| Hoeper, MM; McLaughin, VV | 1 |
| Ewert, R; Felix, S; Opitz, C; Schlag, K; Wensel, R | 1 |
| Agapito, AF; Cacela, D; Feliciano, J; Oliveira, JA; Quininha, J; Sousa, L | 1 |
| Brauchlin, AE; Nicod, LP; Rochat, T; Soccal, PM; Spiliopoulos, A; Trindade, PT | 1 |
| Abbas, A; Boobis, AR; Gibbs, JS; Paul, GA; Wilkins, MR | 1 |
| Bogossian, H; Cortopassi, F; Jardim, C; Martins, B; Rabelo, R; Souza, R; Yaksic, M | 1 |
| Clark, A; Morice, AH; Mulrennan, S | 1 |
| Halank, M; Hoeffken, G; Kolditz, M; Miehlke, S | 1 |
| Bredie, SJ; Heijdra, YF; van den Hoogen, FH; van der Heijden, HF; van Dijk, AP; Vonk, MC | 1 |
| Provencher, S; Simonneau, G; Sitbon, O | 1 |
| Schulze-Neick, I | 1 |
| Erzurum, SC; Lara, AR | 1 |
| Badesch, DB; Barst, RJ; Black, C; Galiè, N; Humbert, M; McLaughlin, VV; Rainisio, M; Rubin, LJ; Simonneau, G; Sitbon, O | 1 |
| Cafferty, F; Dunning, J; George, P; Hughes, R; Morrell, NW; Parameshwar, J; Pepke-Zaba, J | 1 |
| Abman, SH; Barst, RJ; Claussen, LR; Doran, A; Ivy, DD; Morganti, A; Nguyen, N; Rosenzweig, EB; Widlitz, A; Yung, D | 1 |
| Adatia, I | 1 |
| Hammerschmidt, S; Pankau, H; Schauer, J; Seyfarth, HJ; Winkler, J; Wirtz, H | 1 |
| Naeije, R | 1 |
| Channick, RN; Lee, SH | 1 |
| Chakinala, MM | 1 |
| Berger, F; Ewert, P; Gilbert, N; Lange, PE; Luther, YC; Miera, O; Nagdyman, N; Schulze-Neick, I | 1 |
| Hirata, Y; Kanno, K | 1 |
| Halank, M; Hoeffken, G; Kolditz, M; Miehlke, S; Schiemanck, S; Schmeisser, A | 1 |
| Borst, MM; Enke, B; Ewert, R; Gilbert, N; Gruenig, E; Hoeper, MM; Lange, PE; Schulze-Neick, I; Witt, C | 1 |
| Girgis, RE; Hassoun, PM; Krishnan, JA; Mathai, SC; Wigley, FM | 1 |
| Flynn, Y; Haworth, SG; Hislop, AA; Maiya, S | 1 |
| Behr, J; Borst, MM; Ghofrani, A; Halank, M; Hoeper, M; Klose, H; Stähler, G; Wilkens, H; Winkler, J | 1 |
| Hoeper, MM; Kramm, T; Mayer, E; Schäfers, HJ; Schulze, C; Welte, T; Wilkens, H | 1 |
| Adlbrecht, C; Bonderman, D; Jakowitsch, J; Klepetko, W; Lang, IM; Nowotny, R; Skoro-Sajer, N | 1 |
| Hoeper, MM; Markevych, I; Niedermeyer, J; Spiekerkoetter, E; Welte, T | 1 |
| Kayser, SR | 1 |
| Foley, RJ; Metersky, ML | 1 |
| Capron, F; Humbert, M; Jaïs, X; Montani, D; Simonneau, G; Sitbon, O | 1 |
| Howard, LS; Morrell, NW | 1 |
| Mehta, S; Shoemaker, GJ | 1 |
| Autret-Leca, E; Beau-Salinas, F; Garot, D; Ingremeau, V; Jonville-Béra, AP; Le Guellec, C | 1 |
| Whyte, K | 1 |
| Gialafos, EJ; Moyssakis, I; Sfikakis, PP; Taktikou, H; Voteas, V | 1 |
| Akram, MR; Black, CM; Coghlan, JG; Das, C; Davar, J; Denton, CP; Handler, CE; Smith, CJ; Williams, MH | 1 |
| Beer, M; Ertl, G; Geier, O; Hahn, D; Sandstede, J; Schmidt, M; Spindler, M | 1 |
| Dougherty, S; Metcalfe, S; Rasiah, D | 1 |
| Kashour, T; Philipp, R; Sharma, S | 1 |
| Joglekar, A; McCloskey, DA; Riley, DJ; Seibold, JR; Tsai, FS; Wilson, JE | 1 |
| Cabrol, S; Humbert, M; Jaïs, X; Provencher, S; Simonneau, G; Sitbon, O | 1 |
| Fujimoto, K; Ikenoya, S | 1 |
| Barst, RJ; Berekashvili, KK; Horn, EM; Kawut, SM; Lederer, DJ; Rosenzweig, EB; Widlitz, AC | 1 |
| Ewert, R; Halank, M; Hoeffken, G; Kolditz, M; Opitz, C | 1 |
| Riemekasten, G | 1 |
| Olschewski, H | 1 |
| Cochrane, AD; Davis, AM; Penny, DJ; Rose, ML; Simpson, CM; Weintraub, RG; Wilson, SE | 1 |
| Benza, RL; Bourge, RC; Coffey, CS; Pamoukian, SV; Pinderski, LJ; Rayburn, BK; Tallaj, JA | 1 |
| Bonderman, D; Hughes, RJ; Humbert, M; Jais, X; Lang, I; Pepke-Zaba, J; Simonneau, G; Suntharalingam, J | 1 |
| Cozzi, F; Favaro, M; Marotta, H; Ostuni, PA; Sfriso, P; Todesco, S | 1 |
| Comín, J; Gallardo, F; Gil, A; Iglesias, M; Molina, L; Pujol, RM | 1 |
| Groner, F; Matthes, J | 1 |
| Brás-Silva, C; Correia-Pinto, J; Faria, B; Henriques-Coelho, T; Leite-Moreira, AF; Lourenço, AP; Roncon-Albuquerque, R; Wieland, J | 1 |
| Standing, JF | 1 |
| Badesch, D; Barst, RJ; Frost, A; Galie, N; Langleben, D; Lawrence, EC; Naeije, R; Shapiro, S | 1 |
| Hammerschmidt, S; Pankau, H; Seyfarth, HJ; Winkler, J; Wirtz, H | 1 |
| McIntyre, K | 1 |
| Cafferty, FH; Hodgkins, D; Hughes, RJ; Pepke-Zaba, J; Suntharalingam, J | 1 |
| Champion, HC; Hemnes, AR | 1 |
| Celermajer, DS; Hayward, CS; Keogh, AM; Kermeen, F; Kotlyar, E; Macdonald, PS; McNeil, KD; Sy, R | 1 |
| Hughes, R; Humbert, M; Jais, X; Parent, F; Pepke-Zaba, J; Simonneau, G; Suntharalingam, J | 1 |
| Binkert, C; Clozel, M; Hess, P; Iglarz, M; Qiu, C; Rey, M | 1 |
| Archer, SL; Michelakis, ED | 1 |
| Hasegawa, A; Ishikawa, O; Nagai, Y; Nakano, A; Nishimura, S; Yamanaka, M | 1 |
| Lyseng-Williamson, KA; Oldfield, V | 1 |
| Black, CM; Denton, CP; Humbert, M; Rubin, L | 1 |
| Abman, SH | 1 |
| Barbarini, G; Barbaro, G; Giancaspro, G; Grisorio, B; Lucchini, A; Pellicelli, AM | 1 |
| Musch, A | 1 |
| Aiello, R; Caruso, E; Mulè, M; Tamburino, C; Ussia, GP | 1 |
| Goto, K; Maeda, S; Miyauchi, T | 1 |
| Arneson, C; Barst, RJ; Galie, N; Jeffs, R; Naeije, R; Rubin, LJ; Simonneau, G | 1 |
| Coyne, TC | 1 |
| Kirch, W; Pittrow, D | 1 |
| Ewert, R; Opitz, CF | 1 |
| Beghetti, M; Gressin, V; Humbert, M; Iserin, L; Petit, J; Simonneau, G; Sitbon, O | 1 |
| Berger, F; Ewert, P; Fehske, W; Gilbert, N; Lange, PE; Lunze, K; Mebus, S; Miera, O; Mühler, EG; Schulze-Neick, I; Uhlemann, F | 1 |
| Ahmadi-Simab, K; Gross, WL; Hellmich, B | 1 |
| Bobbo, F; Cozzi, F; Durigon, N; Iliceto, S; Marotta, H; Montisci, R; Ruscazio, M; Sfriso, P; Todesco, S | 1 |
| Stähler, G; von Hunnius, P | 1 |
| Eller, P; Fuschelberger, R; Grander, W; Tilg, H | 1 |
| Gerbes, AL; Gülberg, V; Neuhofer, W | 1 |
| Adlbrecht, C; Bonderman, D; Lang, IM; Nowotny, R; Skoro-Sajer, N | 1 |
| Arroliga, AC; Minai, OA | 1 |
| Delgado Jiménez, J; Escribano Subías, P; Flox Camacho, A; Gómez Sánchez, MA; Sáenz de la Calzada, C; Tello de Meneses, R | 1 |
| Cleland, LG; Keogh, AM; McNeil, KD; Perl, K; Weintraub, RG; Williams, TJ; Wlodarczyk, JH | 1 |
| Badesch, DB; Barst, RJ; Channick, RN; Frost, A; Hsu, HH; McLaughlin, VV; Murali, S; Oudiz, RJ; Rubin, LJ; Tapson, VF | 1 |
| Barth, F; Dufour, JF; Gerber, PJ; Nicod, LP; Reichen, J | 1 |
| Beretta, L; Del Papa, N; Mazzone, A; Scorza, R | 1 |
| Gamberi, T; Gensini, GF; Mancia, G; Marchetta, M; Modesti, A; Modesti, PA; Morabito, M; Parati, G; Savia, G; Sofi, F; Vanni, S | 1 |
| Beghini, R; Errico, G; Ilic, S; Padovani, EM; Richelli, C; Rugolotto, S | 1 |
| Channick, RN; Olschewski, H; Rubin, LJ; Seeger, W; Staub, T; Voswinckel, R | 1 |
| Behr, J; Bremer, H; Halank, M; Hoeffken, G; Hoeper, MM; Kluge, S; Leuchte, H; Meyer, FJ; Ripken, F; Seyfarth, HJ; Wensel, R; Wilkens, H | 1 |
| Rich, S | 1 |
| Sastry, BK | 1 |
| Champion, HC; Fisher, MR; Girgis, RE; Hassoun, PM; Housten-Harris, T; Mathai, SC; Zaiman, A | 1 |
| Aranda, A; Ballesteros, S; Cabezón, S; Hinojosa, R; Lage, E; Mogollón, MV; Ordóñez, A; Sobrino, JM | 1 |
| Criner, GJ; Farber, HW; Hill, NS; Klinger, JR; Preston, IR; Steiner, MK; Waxman, AB | 1 |
| Argiento, P; Badagliacca, R; Calabrò, R; D'Alto, M; Fedele, F; Ferrante, F; Mancone, M; Poscia, R; Romeo, E; Russo, MG; Santoro, G; Sarubbi, B; Vizza, CD | 1 |
| Amantéa, SL; Ricachinevsky, CP | 1 |
| Neumann, T; ten Freyhaus, H | 1 |
| Wilkens, H | 1 |
| Ghofrani, HA; Hoeper, MM | 1 |
| Hachulla, E; Humbert, M; Launay, D | 1 |
| Bravo, C; Domingo, E; Gispert, P; Monforte, V; Morell, F; Román, A | 1 |
| Gabbay, E; Reed, A; Williams, TJ | 1 |
| Boyer, L; Chabot, F; Gomez, E; Herve, P; Kheir, A; Le Pavec, J; Sitbon, O | 1 |
| Chen, JS; Chen, RJ; Hsu, HH; Ko, WJ; Kuo, SW; Lee, YC; Wang, JK; Wu, ET; Wu, MH | 1 |
| Barst, RJ; Benza, RL; Keogh, A; Lawrence, EC; Mehta, S; Oudiz, RJ | 1 |
| Bevilacqua, M; Brancaccio, G; Di Chiara, L; Parisi, F; Toscano, A | 1 |
| Gabbay, E; Keogh, AM; McNeil, KD; Williams, TJ; Wlodarczyk, J | 1 |
| Alonso-Pulpón Rivera, L; Gómez Bueno, M; González González, M; Moñivas Palomero, V; Ortiz Uribe, JC; Segovia Cubero, J | 1 |
| Abe, H; Otsuji, Y; Suzuki, Y; Tamura, M; Tanaka, S; Tasaki, H; Yamanaka, A; Yamashita, K | 1 |
| Ashfaq, M; Ausloos, K; Chinnakotla, S; Davis, GL; Klintmalm, GB; Ramsay, M; Rogers, L; Saadeh, S | 1 |
| Izumi, T; Kyotani, S; Sasayama, S; Satoh, T; Tahara, N; Yoshida, S | 1 |
| Langleben, D | 1 |
| Gaine, SP; O'Callaghan, D; O'Callaghan, DS | 1 |
| Auger, WR; Fedullo, PF; Kerr, KM; Kim, NH; Test, VJ | 1 |
| Baloira, A | 1 |
| Fink, CA; Johnson, RF; Loyd, JE; Mullican, AL; Robbins, IM | 1 |
| Lam, YM; Lau, CS; Lo, Y; Mok, MY; Tsang, PL; Wong, WS | 1 |
| Benza, RL; Girgis, RE; Keogh, A; Park, MH | 1 |
| Carlsen, J; Hoeper, MM; Humbert, M; Kiely, DG; Schwierin, B; Segal, ES | 1 |
| Blanco-Aparicio, M; Ferrer-Barba, A; Medrano-López, C; Otero-González, I; Raposo-Sonnenfeld, I | 1 |
| Fragiadaki, KG; Katsichti, P; Mavrikakis, M; Papamichael, C; Sfikakis, PP; Stamatelopoulos, KS; Stefanadis, C; Tousoulis, D | 1 |
| Matsumura, M; Nemoto, S; Nishimura, K; Yoshimura, S | 1 |
| Hirata, Y; Yoshimoto, T | 1 |
| Boonstra, A; Bronzwaer, JG; Gan, CT; Holverda, S; Marcus, JT; Marques, KM; Paulus, WJ; Postmus, PE; Twisk, JW; Vonk-Noordegraaf, A | 1 |
| Diller, GP; Dimopoulos, K; Gatzoulis, MA; Gibbs, JS; Harries, C; Kaya, MG; Koltsida, E; Li, W; Uebing, A | 1 |
| Halank, M; Hoeffken, G; Hoeper, MM; Pletz, MW; Seyfarth, HJ; Spiekerkoetter, E; Welte, T; Wirtz, H | 1 |
| Bou, P; Ghyselen, L; Goissen, C; Krim, G; Maingourd, Y; Storme, L; Tourneux, P | 1 |
| Dandel, M; Grauhan, O; Hetzer, R; Kemper, D; Knosalla, C; Lehmkuhl, HB; Mulahasanovic, S; Weng, Y | 1 |
| Caspi, A; Cotter, G; Kaluski, E; Kobrin, I; Krakover, R; Leitman, M; Milo-Cotter, O; Moriconi, T; Rainisio, M; Reizin, L; Vered, Z; Zimlichman, R | 1 |
| Berger, RM; Duffels, MG; Hillege, HL; Hoendermis, ES; Mulder, BJ; van Loon, RL; Vonk-Noordegraaf, A | 1 |
| Alfano, D; Argiento, P; Calabrò, R; Cotrufo, M; D'Alto, M; Galdieri, N; Maiello, C; Russo, MG; Santoro, G; Sarubbi, B | 1 |
| Brentjens, TE; Bulman, W; Coyle, CM; Dickstein, ML; Emond, J; Horn, EM; Kawut, SM; Wilt, JS | 1 |
| Dhaun, N; Goddard, J; Pollock, DM; Webb, DJ | 1 |
| Iwamoto, M; Kamata, Y; Minota, S | 1 |
| Aubert, JD; Domenighetti, G; Fischler, M; Geiser, T; Huber, L; Rochat, T; Speich, R; Treder, U; Ulrich, S | 1 |
| Callejas-Rubio, JL; Ortego-Centeno, N; Ríos-Fernández, R; Tomás, C | 1 |
| Bizzoca, R; Cinelli, M; Guiducci, S; Iannone, F; Lapadula, G; Matucci-Cerinic, M; Riccardi, MT | 1 |
| Burgess, G; Collings, L; Dingemanse, J; Hoogkamer, H | 1 |
| Berkani, O; Boonstra, A; De Vita, S; Denton, CP; Dölberg, M; Gabrielli, A; Guillevin, L; Morganti, A; Peter, HH; Pope, JE; Riemekasten, G; van den Hoogen, FH | 1 |
| Kawut, SM | 1 |
| Corrocher, R; Lippi, G; Lunardi, C; Montagnana, M; Prati, D; Puccetti, A; Simeoni, S; Tinazzi, E | 1 |
| Anagnostopoulos, CE; Apostolopoulou, SC; Kanakis, MA; Mitropoulos, FA; Rammos, S | 1 |
| Almeida, AR; Almeida, S; Carrageta, M; Cordeiro, P; Cotrim, C; Loureiro, MJ; Miranda, R; Simões, O | 1 |
| Fraser, J; Gabbay, E; McNeil, K | 1 |
| Dimitroula, H; Dimitroulas, T; Giannakoulas, G; Karvounis, H; Koliakos, G; Settas, L; Sfetsios, T | 1 |
| Distler, JH; Distler, O; Hoeper, MM | 1 |
| Dinh-Xuan, AT; Hoeper, MM | 1 |
| Dupuis, J; Hoeper, MM | 1 |
| Amoura, Z; Cacoub, P; Langleben, D | 1 |
| Fischler, M; Huber, LC; Maggiorini, M; Speich, R; Spring, RM; Treder, U; Ulrich, S | 1 |
| Batyraliev, TA; Ekinsi, E; Makhmutkhodzhaev, SA; Pataraia, SA; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA | 1 |
| Diaz-Guzman, E; Dweik, RA; Heresi, GA; Minai, OA | 1 |
| Austin, MJ; Callender, ME; Heneghan, MA; Knisely, AS; McDougall, NI; O'Grady, JG; Rela, M; Sizer, E; Wendon, JA; Wilson, C | 1 |
| Park, MH | 1 |
| Chapman, JT; Mehta, AC; Minai, OA; Sahoo, D | 1 |
| Antonelli-Incalzi, R; Catapano-Minotti, G; Corsonello, A; Guadalupi, G; Spani, R | 1 |
| Durongpisitkul, K; Jakrapanichakul, D; Sompradikul, S | 1 |
| Benza, RL; Bourge, RC; Pamboukian, SV; Rayburn, BK; Tallaj, JA | 1 |
| Beghetti, M; Carlsen, J; Hoeper, MM; Humbert, M; Kiely, DG; Schwierin, B; Segal, ES | 1 |
| Chemla, D; Hervé, P; Humbert, M; Provencher, S; Simonneau, G; Sitbon, O | 1 |
| Brutsche, M; Di Valentino, M; Linka, A; Meyer, A; Rasch, H; Stolz, D; Tamm, M | 1 |
| Chin, KM; de Lemos, JA; Kingman, M; Peshock, R; Reimold, S; Torres, F; Warner, JJ | 1 |
| Kapoor, S | 1 |
| Adnot, S; Clozel, M; Eddahibi, S; Levame, M; Raffestin, B | 1 |
| Chen, SJ; Chen, YF; Dicarlo, VS; Durand, J; Meng, QC; Oparil, S | 1 |
| Clozel, JP; Clozel, M; Hess, P | 1 |
| Clozel, M; Franco-Cereceda, A; Holm, P; Liska, J | 1 |
| Burman, HP; Cahill, PA; O'Donnell, CP; Robotham, JL; Yamamoto, S | 1 |
| Alving, K; Oldner, A; Rudehill, A; Sollevi, A; Wanecek, M; Weitzberg, E | 1 |
| Hemsén, A; Lundberg, JM; Rudehill, A; Wanecek, M; Weitzberg, E | 1 |
| Hill, NS; Klinger, JR; Pietras, L; Warburton, RR | 1 |
| Bechamps, Y; Carteaux, JP; Dolofon, P; Mertes, PM; Roux, S; Schjöth, B; Siaghy, M; Villemot, JP | 1 |
| Lombardi, JP; McNamara, JL; Nelson, DP; Pearl, JM; Raake, JL; Wagner, CJ; Wellmann, SA | 1 |
| Channick, RN; Chiles, PG; Kim, H; Konopka, RG; Marsh, JJ; Morris, TA; Pedersen, CA; Yung, GL | 1 |
| Clozel, M; Roux, S | 1 |
| Jones, R; Keogh, AM; Macdonald, PS; Penny, R; Scroope, F; Wallman, LL; Weber, C; Williamson, DJ | 1 |
| Chen, YF; Oparil, S | 1 |
| Bailey, CL; Channick, RN; Rubin, LJ | 1 |
| SoRelle, R | 1 |
| Albertini, M; Ciminaghi, B; Clement, MG; Mazzola, S | 1 |
| Armstrong, P; Fleming, T; Lindenfeld, J; Lipicky, R | 1 |
| Dupuis, J | 1 |
| Badesch, DB; Bodin, F; Channick, RN; Frost, A; Rainisio, M; Robbins, IM; Roux, S; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Castro, G | 1 |
| Badesch, DB; Barst, RJ; Black, CM; Frost, A; Galie, N; Keogh, A; Landzberg, M; Leconte, I; Pulido, T; Roux, S; Rubin, LJ; Simonneau, G | 1 |
| Newman, JH | 1 |
| Thompson, CA | 1 |
| Heinzl, S | 1 |
| Kim, NH; Rubin, LJ | 1 |
| Roux, S; Rubin, LJ | 1 |
| Berardinelli, C; Kupecz, D | 1 |
| Møller, GM; Ren, X; Wharton, J; Wilkins, MR | 1 |
162 review(s) available for bosentan anhydrous and Pulmonary Hypertension
| Article | Year |
|---|---|
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrosis; Humans; Hypertension, Pulmonary; Neoplasms; Receptors, Endothelin | 2016 |
Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Natriuretic Peptide, Brain; Network Meta-Analysis; Sildenafil Citrate; Treatment Outcome; Vasodilator Agents | 2021 |
Efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn: a Metaanalysis.
Topics: Bosentan; China; Humans; Hypertension, Pulmonary; Infant, Newborn; Treatment Failure | 2022 |
Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Interactions; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension | 2022 |
Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Network Meta-Analysis; Pulmonary Arterial Hypertension; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2023 |
Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis.
Topics: Bosentan; Disease Progression; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Hypoxia; Idiopathic Pulmonary Fibrosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Circulation; Pulmonary Diffusing Capacity; Pulmonary Ventilation; Pyrazoles; Pyrimidines; Sildenafil Citrate; Treatment Failure; Vascular Remodeling; Vasoconstriction | 2019 |
Persistent pulmonary hypertension of the newborn.
Topics: Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Lung; Milrinone; Nitric Oxide; Oxygen; Persistent Fetal Circulation Syndrome; Pulmonary Alveoli; Pulmonary Surfactants; Risk; Sildenafil Citrate; Vascular Resistance; Vasodilator Agents | 2021 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Russia; Sildenafil Citrate | 2020 |
Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
Topics: Bosentan; Child; Cost-Benefit Analysis; Humans; Hypertension, Pulmonary; Pharmaceutical Preparations; Pulmonary Arterial Hypertension; Quality of Life; Sildenafil Citrate | 2021 |
Sarcoidosis-Associated Pulmonary Hypertension.
Topics: Bosentan; Cardiac Catheterization; Disease Management; Echocardiography; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Respiratory Function Tests; Sarcoidosis, Pulmonary; Sulfonamides; Tomography, X-Ray Computed | 2017 |
Pulmonary vasodilator therapy in tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals: case series and review of literature.
Topics: Adult; Antihypertensive Agents; Bosentan; Collateral Circulation; Coronary Angiography; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Atresia; Sulfonamides; Tetralogy of Fallot; Vasodilator Agents; Young Adult | 2017 |
Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sildenafil Citrate; Vasodilator Agents | 2018 |
What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Exercise Tolerance; Hemodynamics; Humans; Hypertension, Pulmonary; Oxygen; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pyridazines; Pyrimidines; Sulfonamides | 2019 |
The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
Topics: Animals; Atherosclerosis; Atrial Fibrillation; Bosentan; Cardiovascular Diseases; Coronary Artery Disease; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Hypertension, Pulmonary; Phenylpropionates; Predictive Value of Tests; Pyridazines; Receptors, Endothelin; Sulfonamides | 2013 |
Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Databases, Factual; Epoprostenol; Humans; Hypertension, Pulmonary; Hypoxia; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Surveys and Questionnaires | 2013 |
Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Compassionate Use Trials; Endarterectomy; Humans; Hypertension, Pulmonary; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2013 |
Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arterial Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Liver; Liver Function Tests; Odds Ratio; Pulmonary Artery; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
[Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Sulfonamides | 2013 |
Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Evaluation; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2014 |
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
[Role of the Rho-kinase pathway in pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Mice; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Rats; rho-Associated Kinases; Signal Transduction; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance | 2014 |
Chronic thromboembolic pulmonary hypertension.
Topics: Angioplasty, Balloon; Bosentan; Chronic Disease; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Thromboembolism | 2014 |
Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.
Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Benzazepines; Bosentan; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-2; Endothelin-3; Endothelin-Converting Enzymes; Endothelins; Epigenesis, Genetic; Humans; Hypertension, Pulmonary; Metalloendopeptidases; Neoplasms; Peptide Fragments; Phenylpropionates; Pyridazines; Pyrimidines; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents | 2014 |
Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Topics: Animals; Bosentan; Drug Interactions; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Pyrimidines; Sulfonamides | 2015 |
[Management of borderline pulmonary arterial hypertension associated with connective tissue diseases].
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Disease Susceptibility; Diuretics; Early Diagnosis; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Nitric Oxide Synthase Type II; Polymorphism, Genetic; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents | 2014 |
Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Monitoring; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Pyrimidines; Risk; Sulfonamides | 2015 |
Novel Strategies in the Treatment of Pulmonary Arterial Hypertension.
Topics: Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Phenylpropionates; Prognosis; Pulmonary Circulation; Pyridazines; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vascular Resistance | 2016 |
[Pregnant woman with pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Iloprost; Phosphodiesterase Inhibitors; Pregnancy; Pregnancy Complications; Sildenafil Citrate; Sulfonamides | 2015 |
[Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan].
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Outcome Assessment, Health Care; Prognosis; Pulmonary Circulation; Sulfonamides; Vascular Resistance | 2015 |
Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters.
Topics: Anion Transport Proteins; Bosentan; Cytochrome P-450 CYP3A; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Models, Biological; Sulfonamides; Treatment Outcome | 2016 |
Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants.
Topics: Bosentan; Endothelin Receptor Antagonists; Extracorporeal Membrane Oxygenation; Humans; Hypertension, Pulmonary; Infant, Newborn; Infant, Premature; Nitrous Oxide; Randomized Controlled Trials as Topic; Sulfonamides; Term Birth; Treatment Failure | 2016 |
Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.
Topics: Bosentan; Chronic Disease; Comorbidity; Endarterectomy; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Sulfonamides | 2016 |
Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials, Phase III as Topic; Drug Interactions; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2008 |
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Phenylpropionates; Pulmonary Artery; Pyridazines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Treatment Outcome; Vascular Resistance; Walking | 2008 |
Bosentan in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2008 |
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Current pharmacological treatment of pulmonary arterial hypertension.
Topics: Bosentan; Diuretics; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
[Specific drugs for the treatment of pulmonary arterial hypertension - current status].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2008 |
[Combination therapy in patients with pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Prostaglandins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2008 |
[Update in pulmonary hypertension associated with connective tissue diseases - a systematic literature review].
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Connective Tissue Diseases; Drug Therapy, Combination; Echocardiography; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Piperazines; Prevalence; Prognosis; Purines; Respiratory Function Tests; Sensitivity and Specificity; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Vasodilator Agents | 2008 |
Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Bosentan; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Prognosis; Pulmonary Artery; Sulfonamides | 2008 |
HIV-related pulmonary arterial hypertension: clinical presentation and management.
Topics: Antihypertensive Agents; Antiretroviral Therapy, Highly Active; Bosentan; CD4 Lymphocyte Count; Epoprostenol; Female; HIV Infections; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Pulmonary Circulation; Receptors, Endothelin; Severity of Illness Index; Substance Abuse, Intravenous; Sulfonamides; Survival Analysis; Treatment Outcome | 2008 |
Bosentan for idiopathic pulmonary fibrosis.
Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Pulmonary Fibrosis; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
[Endothelin receptor antagonist].
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Sulfonamides | 2008 |
[Pulmonary arterial hypertension related to systemic sclerosis in 2008].
Topics: Altitude; Antihypertensive Agents; Bosentan; Echocardiography; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; France; Humans; Hypertension, Pulmonary; Hypoxia; Oxygen; Phosphodiesterase 5 Inhibitors; Prognosis; Scleroderma, Systemic; Sulfonamides | 2009 |
Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Patient Compliance; Patient Satisfaction; Phenylpropionates; Pyridazines; Quality of Life; Receptors, Endothelin; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2009 |
Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Exercise Test; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Circulation; Sulfonamides | 2009 |
Bosentan in pediatric patients with pulmonary arterial hypertension.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Exercise Tolerance; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Sulfonamides | 2009 |
[Potential role of endothelin in patients with acute pulmonary embolism and chronic thromboembolic pulmonary hypertension].
Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Endothelins; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Sulfonamides | 2009 |
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Exercise Tolerance; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones | 2009 |
Vasculopathy and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Churg-Strauss Syndrome; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Scleroderma, Systemic; Sjogren's Syndrome; Sulfonamides; Vasculitis | 2009 |
Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Design; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Patents as Topic; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2009 |
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Bosentan; Endothelin A Receptor Antagonists; Exercise Tolerance; Humans; Hypertension, Pulmonary; Quality of Life; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Vascular Resistance | 2009 |
Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Drug Interactions; Humans; Hypertension, Pulmonary; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Sulfonamides | 2009 |
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; United States; Vasodilator Agents | 2009 |
Bosentan for chronic thromboembolic pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides; Thromboembolism | 2009 |
Pulmonary hypertension in thoracic surgical patients.
Topics: Anesthesia, Inhalation; Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thoracic Surgical Procedures; Vasodilator Agents | 2010 |
Bosentan: in pediatric patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Area Under Curve; Bosentan; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Endothelin A Receptor Antagonists; Exercise; Half-Life; Humans; Hypertension, Pulmonary; Metabolic Clearance Rate; Pediatrics; Sulfonamides | 2010 |
Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Epoprostenol; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Time Factors; Treatment Outcome | 2010 |
Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Case-Control Studies; Chronic Disease; Cohort Studies; Double-Blind Method; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; Pulmonary Embolism; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vascular Resistance | 2010 |
[Guidelines for the diagnosis and treatment of pulmonary hypertension].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Piperazines; Practice Guidelines as Topic; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
Bosentan.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Drug Interactions; Endothelin Receptor Antagonists; Endothelins; Evidence-Based Medicine; Exercise Tolerance; Humans; Hypertension, Pulmonary; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2010 |
HIV and pulmonary arterial hypertension: a systematic review.
Topics: Adolescent; Adult; Antihypertensive Agents; Antiretroviral Therapy, Highly Active; Bosentan; Cardiomegaly; CD4 Lymphocyte Count; Child; Cohort Studies; Confounding Factors, Epidemiologic; Databases, Bibliographic; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Echocardiography; Electrocardiography; Epoprostenol; Female; Hemodynamics; HIV Infections; Humans; Hypertension, Pulmonary; Male; Prevalence; Radiography; Reverse Transcriptase Inhibitors; Sulfonamides; Survival Rate; Treatment Outcome | 2010 |
Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2010 |
Review on bosentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Interactions; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides | 2010 |
Pulmonary arterial hypertension in women.
Topics: Abortion, Therapeutic; Adult; Anticoagulants; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Calcium Channel Blockers; Contraception; Dyspnea; Endothelin A Receptor Antagonists; Female; Fetal Growth Retardation; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Middle Aged; Phosphodiesterase Inhibitors; Pregnancy; Pregnancy Complications, Cardiovascular; Preimplantation Diagnosis; Prognosis; Prostaglandins I; Sex Distribution; Sulfonamides; Ultrasonography | 2010 |
[The ideal dosage form for clinical study. Bosentan in pediatric patients].
Topics: Aging; Antihypertensive Agents; Bosentan; Chemistry, Pharmaceutical; Child; Dosage Forms; Humans; Hypertension, Pulmonary; Sulfonamides | 2010 |
Bosentan for the treatment of adult pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Comorbidity; Disease Progression; Endothelin Receptor Antagonists; Endothelin-1; Exercise Tolerance; Hemodynamics; Humans; Hypertension, Pulmonary; Prognosis; Quality of Life; Receptors, Endothelin; Sulfonamides | 2011 |
Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2011 |
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
Topics: Adult; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Sulfonamides | 2011 |
Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sulfonamides | 2011 |
Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Economics, Pharmaceutical; Humans; Hypertension, Pulmonary; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sulfonamides; Survival; Walking | 2011 |
Lengthy diagnostic challenge in a rare case of pulmonary veno-occlusive disease: case report and review of the literature.
Topics: Adult; Antihypertensive Agents; Biopsy; Bosentan; Cardiotonic Agents; Diagnosis, Differential; Digoxin; Diuretics; Drug Therapy, Combination; Dyspnea; Humans; Hypertension, Pulmonary; Male; Pulmonary Heart Disease; Pulmonary Veno-Occlusive Disease; Sulfonamides; Time Factors; Tomography, X-Ray Computed | 2011 |
Advances in the management of pediatric pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Child; Citrulline; Drug Therapy, Combination; Endothelium, Vascular; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Muscle Contraction; Persistent Fetal Circulation Syndrome; Phosphodiesterase 5 Inhibitors; Piperazines; PPAR gamma; Prostaglandins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasoconstriction; Ventricular Function, Right | 2011 |
Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Interactions; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sulfonamides | 2012 |
[Progress in pharmacotherapy of pulmonary arterial hypertension in children].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Sulfonamides | 2012 |
Efficacy of bosentan therapy for segmental pulmonary artery hypertension due to major aortopulmonary collateral arteries in children.
Topics: Aorta; Bosentan; Child; Collateral Circulation; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Radiography; Sulfonamides; Tetralogy of Fallot; Treatment Outcome; Vasodilator Agents | 2012 |
Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
Topics: Acenocoumarol; Anticoagulants; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents; Withholding Treatment | 2013 |
Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Bosentan; Drug Design; Drug Monitoring; Endothelin Receptor Antagonists; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sulfonamides | 2012 |
Early detection and management of pulmonary arterial hypertension.
Topics: Anemia, Sickle Cell; Antihypertensive Agents; Bosentan; Early Diagnosis; Echocardiography, Doppler; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; Natriuretic Peptide, Brain; Peptide Fragments; Piperazines; Practice Guidelines as Topic; Purines; Respiratory Function Tests; Risk Factors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2012 |
Pulmonary hypertension in left heart disease.
Topics: Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Electrocardiography; Endothelin A Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Exercise Test; Heart Valve Prosthesis; Humans; Hypertension, Pulmonary; Mitral Valve; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Wedge Pressure; Radiography, Thoracic; Stroke Volume; Sulfonamides; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Left; Weight Loss | 2012 |
Pulmonary arterial hypertension associated with congenital heart disease.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Comorbidity; Down Syndrome; Eisenmenger Complex; Endothelium, Vascular; Epoprostenol; Health Behavior; Heart Defects, Congenital; Heart Transplantation; Humans; Hypertension, Pulmonary; Lung Transplantation; Oxygen Inhalation Therapy; Phosphodiesterase 5 Inhibitors; Piperazines; Practice Guidelines as Topic; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thrombosis | 2012 |
Targeting mediators of vascular injury in scleroderma.
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Clinical Trials as Topic; Endothelin-1; Endothelium, Vascular; Epoprostenol; Humans; Hypertension, Pulmonary; Muscle, Smooth, Vascular; Reactive Oxygen Species; Scleroderma, Systemic; Sulfonamides | 2002 |
Advances in the treatment of secondary pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Clinical Trials as Topic; Echocardiography; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2003 |
Therapy for primary pulmonary hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Patient Selection; Prescription Fees; Sulfonamides; Vasomotor System | 2003 |
Endothelin and endothelin receptor antagonists in systemic rheumatic disease.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Controlled Clinical Trials as Topic; CREST Syndrome; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Receptors, Endothelin; Sequence Homology, Amino Acid; Signal Transduction; Sulfonamides | 2003 |
The endothelin system in pulmonary hypertension.
Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Receptors, Endothelin; Sulfonamides | 2003 |
Pulmonary arterial hypertension--the primary pulmonary hypertension syndromes.
Topics: Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Endothelins; Epoprostenol; Humans; Hypertension, Pulmonary; Sulfonamides; Vasodilator Agents | 2003 |
[Endothelin receptor blockers--one more agent for the treatment of pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Carboxylic Acids; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Indans; Pyridines; Sulfonamides; Tetrazoles; Vasodilator Agents | 2003 |
Drug therapy for pulmonary arterial hypertension: what's on the menu today?
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2003 |
Treatment of pulmonary arterial hypertension: a preliminary decision analysis.
Topics: Antihypertensive Agents; Bosentan; Decision Support Techniques; Epoprostenol; Fees, Pharmaceutical; Humans; Hypertension, Pulmonary; Markov Chains; Quality-Adjusted Life Years; Sulfonamides | 2003 |
Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Pulmonary Artery; Pulmonary Fibrosis; Sulfonamides | 2003 |
Bosentan.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides | 2002 |
The endothelin system in pulmonary arterial hypertension.
Topics: Animals; Bosentan; Endothelial Cells; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Infant, Newborn; Isoxazoles; Models, Animal; Muscle, Smooth, Vascular; Pulmonary Circulation; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Thiophenes | 2004 |
Bosentan: a novel agent for the treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Male; Randomized Controlled Trials as Topic; Sulfonamides | 2004 |
Current medical treatment of pulmonary arterial hypertension.
Topics: Algorithms; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Platelet Aggregation Inhibitors; Sulfonamides | 2004 |
[Treatment of pulmonary arterial hypertension associated to systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Calcium; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Scleroderma, Systemic; Sulfonamides | 2004 |
Bosentan.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Controlled Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2004 |
End points in pulmonary arterial hypertension: the way forward.
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Coronary Circulation; Diagnostic Imaging; Endpoint Determination; Exercise Tolerance; Hemodynamics; Humans; Hypertension, Pulmonary; Outcome Assessment, Health Care; Prognosis; Pulmonary Artery; Quality of Life; Research Design; Sulfonamides | 2004 |
Bosentan therapy for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Interactions; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides | 2004 |
[Treatment of pulmonary arterial hypertension in children].
Topics: Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Catheter Ablation; Child; Epoprostenol; Heart Atria; Humans; Hypertension, Pulmonary; Lung Transplantation; Patient Selection; Pediatrics; Piperazines; Purines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2004 |
Endothelin and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelin Receptor Antagonists; Endothelins; Female; Humans; Hypertension, Pulmonary; Male; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Sulfonamides; Survival Analysis; Treatment Outcome | 2004 |
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Sulfonamides | 2004 |
[Treatments for pulmonary arterial hypertension].
Topics: Algorithms; Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Diuretics; Endothelin Receptor Antagonists; Forecasting; Heart Septum; Humans; Hypertension, Pulmonary; Injections, Intravenous; Lung Transplantation; Phosphodiesterase Inhibitors; Prospective Studies; Prostaglandins I; Randomized Controlled Trials as Topic; Retrospective Studies; Sulfonamides | 2004 |
[Pathophysiological significance of endothelin in pulmonary hypertension].
Topics: Biomarkers; Bosentan; Cell Division; Drug Design; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Muscle Contraction; Muscle, Smooth, Vascular; Severity of Illness Index; Sulfonamides | 2004 |
The right ventricle in pulmonary hypertension.
Topics: Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Epoprostenol; Female; Heart Failure; Heart Function Tests; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Prognosis; Risk Assessment; Severity of Illness Index; Stroke Volume; Sulfonamides; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function | 2005 |
Endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Child; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2005 |
When cure is care: diagnosis and management of pulmonary arterial hypertension.
Topics: Adenosine; Algorithms; Antihypertensive Agents; Bosentan; Bronchodilator Agents; Calcium Channel Blockers; Decision Trees; Diagnosis, Differential; Epoprostenol; Fatal Outcome; Fenfluramine; Health Promotion; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Nitric Oxide; Nurse Practitioners; Primary Health Care; Prognosis; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sulfonamides; Vasodilator Agents | 2005 |
[Portopulmonary hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Epoprostenol; Hepatopulmonary Syndrome; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Lung; Pulmonary Wedge Pressure; Sulfonamides; Survival Rate; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2005 |
Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Receptors, Endothelin; Sulfonamides | 2005 |
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Cohort Studies; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Middle Aged; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents; Ventricular Dysfunction, Right | 2005 |
Endothelin antagonism in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2005 |
Changing the prognosis of pulmonary arterial hypertension: impact of medical therapy.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Clinical Trials as Topic; Epoprostenol; Humans; Hypertension, Pulmonary; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis; Warfarin | 2005 |
[Endothelin].
Topics: Animals; Arteriosclerosis; Biomarkers; Bosentan; Diagnostic Techniques, Endocrine; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Receptors, Endothelin; Reference Values; Sulfonamides | 2005 |
Combination drug therapy in the management of pulmonary arterial hypertension.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Cardiotonic Agents; Diuretics; Drug Monitoring; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prostaglandins; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2005 |
[Pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Electrocardiography; Epoprostenol; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Sulfonamides; Treatment Outcome | 2005 |
New therapeutic agents for pulmonary vascular disease.
Topics: Adult; Antihypertensive Agents; Arginine; Bosentan; Child; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Sulfonamides | 2005 |
[Pharmacological characteristics and clinical efficacy of bosentan].
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; In Vitro Techniques; Nitric Oxide Synthase; Randomized Controlled Trials as Topic; Sulfonamides; Vasoconstriction | 2005 |
[Diagnosis and treatment of pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Brain Infarction; Calcium Channel Blockers; Humans; Hypertension, Pulmonary; Iloprost; Life Expectancy; Pulmonary Heart Disease; Quality of Life; Sulfonamides | 2006 |
[Bosentan: a new pillar in the treatment of pulmonary hypertension?].
Topics: Adult; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Time Factors; Treatment Outcome; Walking | 2006 |
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Drug Administration Schedule; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Receptors, Endothelin; Sulfonamides | 2006 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Receptors, Endothelin; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides | 2006 |
Pulmonary hypertension in older children: new approaches and therapies.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Cardiac Catheterization; Child; Cyclic Nucleotide Phosphodiesterases, Type 5; Echocardiography; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase Inhibitors; Pulmonary Wedge Pressure; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
[Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides | 2006 |
[Endothelin].
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Hypertension; Hypertension, Pulmonary; Receptors, Endothelin; Sulfonamides | 2006 |
Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cell Division; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Lung; Pulmonary Fibrosis; Sulfonamides; Thiophenes; Vasoconstriction; Vasodilation | 2006 |
Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Phosphodiesterase Inhibitors; Receptors, Endothelin; Sulfonamides; Vasodilator Agents | 2006 |
Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Liver Transplantation; Pulmonary Circulation; Sulfonamides; Treatment Outcome | 2006 |
Endothelin.
Topics: Amino Acid Sequence; Animals; Antihypertensive Agents; Aspartic Acid Endopeptidases; Atherosclerosis; Binding Sites; Bosentan; Endothelin-Converting Enzymes; Endothelins; Endothelium, Vascular; Humans; Hypertension; Hypertension, Pulmonary; Metalloendopeptidases; Molecular Sequence Data; Muscle, Smooth, Vascular; Receptors, Endothelin; Signal Transduction; Sulfonamides; Vasoconstrictor Agents; Viper Venoms | 2006 |
The current treatment of pulmonary arterial hypertension: time to redefine success.
Topics: Bosentan; Endothelins; Epoprostenol; Exercise Test; Humans; Hypertension, Pulmonary; Long-Term Care; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Pharmacologic treatment for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Disease Progression; Drug Therapy, Combination; Endothelin-1; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Prostaglandins; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Child; Endothelin Receptor Antagonists; Endothelium-Dependent Relaxing Factors; Epoprostenol; Humans; Hypertension, Pulmonary; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Purines; Receptors, Endothelin; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Survival Rate; Thiophenes | 2006 |
[Pulmonary hypertension in HIV patients].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Cyclic Nucleotide Phosphodiesterases, Type 5; HIV Infections; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Prevalence; Prognosis; Prostaglandins; Sulfonamides | 2006 |
[Pulmonary arterial hypertension following pulmonary thromboembolism].
Topics: Antihypertensive Agents; Bosentan; Endarterectomy; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Pulmonary Embolism; Purines; Recurrence; Sildenafil Citrate; Splenectomy; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
[Drug combination treatment for pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Drug Synergism; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
[Pulmonary arterial hypertension and systemic sclerosis].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cohort Studies; Echocardiography, Doppler; Epoprostenol; European Union; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prevalence; Prognosis; Purines; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents; World Health Organization | 2006 |
Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006.
Topics: Adolescent; Adult; Aged; Arterioles; Australia; Bosentan; Cardiac Catheterization; Diagnostic Imaging; Disease Progression; Dyspnea; Endothelin A Receptor Antagonists; Epoprostenol; Exercise Test; Female; Forecasting; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Nitric Oxide; Piperazines; Prognosis; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
[Porto-pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Echocardiography; Epoprostenol; Humans; Hypertension, Portal; Hypertension, Pulmonary; Oxygen Inhalation Therapy; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2006 |
Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2007 |
Combination therapy and new types of agents for pulmonary arterial hypertension.
Topics: Adrenomedullin; Angiopoietin-1; Antihypertensive Agents; Benzamides; Bosentan; Drug Therapy, Combination; Eicosanoids; Epoprostenol; Genetic Therapy; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Piperazines; Platelet Aggregation Inhibitors; Prostaglandins; Protein Serine-Threonine Kinases; Purines; Pyrimidines; rho-Associated Kinases; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sildenafil Citrate; Sulfonamides; Sulfones; Vasoactive Intestinal Peptide; Vasodilator Agents | 2007 |
Chronic thromboembolic pulmonary hypertension.
Topics: Antibodies, Antiphospholipid; Bosentan; Cardiac Catheterization; Chronic Disease; Endarterectomy; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Physical Exertion; Pulmonary Embolism; Risk Factors; Sulfonamides; Thrombectomy | 2007 |
Management of pulmonary arterial hypertension with a focus on combination therapies.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endothelin-1; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Piperazines; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis | 2007 |
[Bosentan for treatment of heart failure].
Topics: Animals; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Hypertension, Pulmonary; Sulfonamides; Ventricular Remodeling | 2007 |
Selective and mixed endothelin receptor antagonism in cardiovascular disease.
Topics: Animals; Bosentan; Clinical Trials as Topic; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Models, Biological; Sulfonamides; Thiophenes | 2007 |
Review of bosentan in the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Endothelin-1; Humans; Hypertension, Pulmonary; Pediatrics; Quality of Life; Sulfonamides | 2007 |
Endothelin receptor antagonists in pulmonary arterial hypertension.
Topics: Animals; Bosentan; Clinical Trials, Phase III as Topic; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Severity of Illness Index; Sulfonamides; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2008 |
[Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes; Ventricular Dysfunction, Right | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
[The pharmacology of endothelin and its antagonist bosentan].
Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Sulfonamides | 2000 |
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
Medical management of primary pulmonary hypertension.
Topics: Bosentan; Calcium Channel Blockers; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2002 |
Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Pulmonary Artery; Sulfonamides; Thiophenes | 2002 |
Bosentan: a dual endothelin receptor antagonist.
Topics: Animals; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Hypertension, Pulmonary; Models, Animal; Sulfonamides | 2002 |
Developments in therapeutics for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Endothelins; Forecasting; Genetic Therapy; Genotype; Humans; Hypertension, Pulmonary; Mutation; Phosphodiesterase Inhibitors; Piperazines; Polymorphism, Genetic; Purines; Receptors, Transforming Growth Factor beta; Serotonin; Sildenafil Citrate; Sulfonamides; Sulfones; Transcription, Genetic; Vasodilator Agents | 2002 |
106 trial(s) available for bosentan anhydrous and Pulmonary Hypertension
| Article | Year |
|---|---|
The efficacy of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease: A protocol of randomized controlled trial.
Topics: Bosentan; Child; Drug Therapy, Combination; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Vardenafil Dihydrochloride | 2021 |
Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Arterial Pressure; Bosentan; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Least-Squares Analysis; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Recovery of Function; Sildenafil Citrate; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Walk Test | 2017 |
Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
Topics: Activities of Daily Living; Aged; Bosentan; Echocardiography; Endothelin Receptor Antagonists; Female; Heart; Hospitalization; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Prospective Studies; Respiratory Function Tests; Sulfonamides; Survival Analysis; Treatment Outcome | 2017 |
[Effect of bosentan on the clinical status and cellular immunity of patients with idiopathic pulmonary hypertension].
Topics: Adult; Antihypertensive Agents; Bosentan; Echocardiography; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Immunity, Cellular; Male; Prospective Studies; Sulfonamides; T-Lymphocytes; Treatment Outcome; Vascular Resistance | 2013 |
Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.
Topics: Adult; Antihypertensive Agents; Biological Availability; Bosentan; Chemistry, Pharmaceutical; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Design; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Male; Middle Aged; Predictive Value of Tests; Sulfonamides; Tablets | 2013 |
[First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study].
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
Bosentan for mild pulmonary vascular disease in ASD patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Double-Blind Method; Female; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pilot Projects; Prospective Studies; Sulfonamides; Vascular Resistance | 2013 |
Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Endarterectomy; Exercise Test; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Middle Aged; Netherlands; Pilot Projects; Pulmonary Embolism; Recovery of Function; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Waiting Lists | 2013 |
Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sarcoidosis, Pulmonary; Sulfonamides | 2014 |
Effect of bosentan on pulmonary hypertension secondary to systolic heart failure.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome; Vascular Resistance | 2013 |
[Efficacy of endothelin receptor antagonist bosentan on the long-term prognosis in patients after Fontan operation].
Topics: Adolescent; Bosentan; Child; Child, Preschool; Endothelin Receptor Antagonists; Female; Fontan Procedure; Humans; Hypertension, Pulmonary; Male; Prognosis; Sulfonamides; Treatment Outcome | 2013 |
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Topics: Antihypertensive Agents; Bosentan; Disease Progression; Double-Blind Method; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Risk Factors; Sulfonamides; Survival Rate; Treatment Outcome | 2014 |
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bosentan; Child; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Prospective Studies; Sulfonamides; Survival Rate; Thiophenes; Time Factors; Treatment Outcome; United States; Uric Acid; Young Adult | 2014 |
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension, Pulmonary; Idiopathic Interstitial Pneumonias; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Sulfonamides; Treatment Outcome; Vascular Resistance; Young Adult | 2014 |
[Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Survival Rate; Treatment Outcome | 2014 |
Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Vascular Resistance; Young Adult | 2015 |
[Efficacy of oral bosentan for treatment of congenital heart disease-associated pulmonary arterial hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Sulfonamides | 2014 |
Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bosentan; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Sildenafil Citrate; Sulfonamides; Vascular Resistance; Young Adult | 2015 |
[Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis].
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Cardiac Catheterization; Echocardiography; Exercise; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Circulation; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2015 |
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sildenafil Citrate; Sulfonamides; Switzerland; Treatment Outcome; Vasodilator Agents | 2015 |
Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension.
Topics: Adult; Bosentan; Drug Therapy, Combination; Exercise; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyridazines; Sildenafil Citrate; Sulfonamides | 2016 |
Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis.
Topics: Antihypertensive Agents; Bosentan; Child; Dried Blood Spot Testing; Female; Humans; Hypertension, Pulmonary; Male; Plasma; Sulfonamides | 2016 |
Feasibility of Repairing Defects Followed by Treatment with Pulmonary Hypertension-specific Drugs (Repair and Treat) in Patients with Pulmonary Hypertension Associated with Atrial Septal Defect: Study Protocol for Interventional Trial.
Topics: Antihypertensive Agents; Bosentan; Clinical Protocols; Drug Administration Schedule; Feasibility Studies; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Prospective Studies; Sildenafil Citrate; Sulfonamides | 2016 |
Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial).
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Heart Failure, Diastolic; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pilot Projects; Sulfonamides | 2017 |
Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Male; Pulmonary Artery; Quality of Life; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Walk Test | 2017 |
A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.
Topics: Administration, Oral; Antihypertensive Agents; Area Under Curve; Bosentan; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Infant; Male; Prospective Studies; Sulfonamides | 2017 |
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome; Vascular Resistance; Walking | 2008 |
Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol.
Topics: Adult; Antihypertensive Agents; Bosentan; Child; Drug Synergism; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2008 |
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Child; Disease-Free Survival; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver Function Tests; Male; Middle Aged; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes; Transaminases; Treatment Outcome; Young Adult | 2009 |
Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Topics: Adult; Aged; Antihypertensive Agents; Arteries; Bosentan; Connective Tissue Diseases; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Mixed Connective Tissue Disease; Prospective Studies; Pulmonary Artery; Raynaud Disease; Scleroderma, Systemic; Skin Diseases; Sulfonamides; Ulcer; Vasculitis | 2009 |
[Effects of bosentan in treatment of pulmonary arterial hypertension: a pilot study of 21 patients].
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Prospective Studies; Pulmonary Artery; Sulfonamides; Treatment Outcome; Vascular Resistance; Young Adult | 2008 |
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Disease Progression; Double-Blind Method; Endarterectomy; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Severity of Illness Index; Sulfonamides; Thromboembolism | 2008 |
Bosentan for patients with chronic thromboembolic pulmonary hypertension.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Bosentan; Chronic Disease; Diuretics; Drug Therapy, Combination; Dyspnea; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Sulfonamides; Treatment Outcome; Walking; Young Adult | 2009 |
Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease.
Topics: Aged; Antihypertensive Agents; Bosentan; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Plethysmography; Pulmonary Disease, Chronic Obstructive; Pulmonary Wedge Pressure; Sulfonamides; Treatment Outcome; Vascular Resistance | 2009 |
Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis.
Topics: Adult; Antihypertensive Agents; Bosentan; Boston; Canada; Double-Blind Method; Eisenmenger Complex; Exercise; Female; Heart Septal Defects, Atrial; Heart Septal Defects, Ventricular; Hemodynamics; Humans; Hypertension, Pulmonary; Italy; Male; Middle Aged; Netherlands; Ontario; Oximetry; Pulmonary Circulation; Pulmonary Wedge Pressure; Sulfonamides; Switzerland; Treatment Outcome; United Kingdom; Vascular Resistance | 2010 |
Tadalafil therapy for pulmonary arterial hypertension.
Topics: Adult; Aged; Bosentan; Carbolines; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Quality of Life; Sulfonamides; Tadalafil; Treatment Outcome | 2009 |
The effect of bosentan in patients with a failing Fontan circulation.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Female; Follow-Up Studies; Fontan Procedure; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Pulmonary Circulation; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Endarterectomy; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Thromboembolism | 2010 |
Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study.
Topics: Antihypertensive Agents; Bosentan; Drug Interactions; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Models, Cardiovascular; Nitric Oxide; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Bosentan; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2009 |
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Epidemiologic Methods; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2010 |
Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.
Topics: Administration, Oral; Airway Obstruction; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Sulfonamides; Treatment Outcome | 2009 |
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; China; Female; Humans; Hypertension, Pulmonary; Male; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2010 |
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.
Topics: Adult; Anemia, Sickle Cell; Antihypertensive Agents; Bosentan; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Sulfonamides; Vascular Resistance | 2010 |
Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Bosentan; Contraindications; Heart Failure; Heart Transplantation; Humans; Hypertension, Pulmonary; Piperazines; Prospective Studies; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents | 2010 |
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Young Adult | 2010 |
Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Child, Preschool; Female; Fontan Procedure; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Male; Pulmonary Artery; Sulfonamides; Treatment Outcome; Vascular Resistance | 2010 |
Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Laser-Doppler Flowmetry; Male; Middle Aged; Raynaud Disease; Regional Blood Flow; Scleroderma, Systemic; Skin; Sulfonamides | 2010 |
Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
Topics: Administration, Oral; Adult; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eisenmenger Complex; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Piperazines; Prospective Studies; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Treatment Outcome; Vascular Resistance | 2012 |
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Tadalafil; Treatment Outcome | 2011 |
[The efficacy and safety of bosentan therapy for Chinese patients with idiopathic pulmonary arterial hypertension: an open-label, prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Asian People; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Young Adult | 2011 |
Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Pulmonary Artery; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vascular Resistance; Young Adult | 2011 |
Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Ethnicity; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Phenylpropionates; Prevalence; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Sex Factors; Sulfonamides; Thiophenes; Treatment Outcome; United States; Walking; Young Adult | 2012 |
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Double-Blind Method; Drug Therapy, Combination; Epoprostenol; Female; Headache; Humans; Hypertension, Pulmonary; Incidence; Longitudinal Studies; Male; Middle Aged; Nausea; Physical Endurance; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2011 |
A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Prospective Studies; Sulfonamides; Treatment Outcome | 2012 |
Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Exercise Test; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Middle Aged; Pilot Projects; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2012 |
Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
Topics: Aged; Angioplasty; Antihypertensive Agents; Bosentan; Chronic Disease; Combined Modality Therapy; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2012 |
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Walking; Young Adult | 2012 |
Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Sulfonamides; Tadalafil; Treatment Outcome; Vasodilator Agents | 2012 |
Right ventricular function predicts clinical response to specific vasodilator therapy in patients with pulmonary hypertension.
Topics: Adult; Bosentan; Echocardiography; Female; Humans; Hypertension, Pulmonary; Male; Piperazines; Purines; Reproducibility of Results; Sensitivity and Specificity; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Right; Ventricular Function, Right | 2013 |
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Female; Humans; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Hypertrophy, Right Ventricular; Male; Middle Aged; Sulfonamides; Ventricular Function, Left; Ventricular Function, Right | 2003 |
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
Topics: Adolescent; Analysis of Variance; Antihypertensive Agents; Body Weight; Bosentan; Child; Child, Preschool; Drug Administration Schedule; Female; Half-Life; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2003 |
Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Topics: Administration, Inhalation; Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Pilot Projects; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2003 |
Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Bosentan; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Sulfonamides; Vascular Resistance | 2004 |
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Safety; Sulfonamides; Time Factors | 2004 |
Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension.
Topics: Adult; Asian People; Blood Pressure; Bosentan; Cardiac Output; Dyspnea; Endothelin Receptor Antagonists; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Pharmacokinetics; Quality of Life; Sulfonamides; Vascular Resistance; White People | 2005 |
Survival with first-line bosentan in patients with primary pulmonary hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Double-Blind Method; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Proportional Hazards Models; Respiratory Function Tests; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
Topics: Adult; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Organ Size; Phosphodiesterase Inhibitors; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Exercise; Exercise Tolerance; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Oximetry; Sulfonamides; Treatment Outcome | 2005 |
The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2005 |
Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Biomarkers; Bosentan; Brazil; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Quality of Life; Sulfonamides; Surveys and Questionnaires; Walking | 2005 |
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Prospective Studies; Prostaglandins; Sulfonamides; Ultrasonography; Vasodilator Agents | 2005 |
Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children.
Topics: Antihypertensive Agents; Bosentan; Child; Child, Preschool; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Male; Palliative Care; Pilot Projects; Pulmonary Artery; Sulfonamides; Treatment Outcome | 2005 |
Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Female; Heart Diseases; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides | 2005 |
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Topics: Aged; Anticoagulants; Antihypertensive Agents; Bosentan; Diuretics; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Pilot Projects; Sulfonamides; Thromboembolism; Vascular Resistance; Walking | 2005 |
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antihypertensive Agents; Aspartate Aminotransferases; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Liver Function Tests; Male; Middle Aged; Sulfonamides; Thromboembolism; Walking | 2005 |
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Topics: Administration, Inhalation; Algorithms; Antihypertensive Agents; Bosentan; Decision Support Systems, Clinical; Drug Administration Schedule; Drug Therapy, Combination; Female; Germany; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2006 |
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Endothelin A Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Risk Assessment; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
Does rapid dose titration affect the hepatic safety profile of Bosentan?
Topics: Alanine Transaminase; Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Drug Administration Schedule; Female; Humans; Hypertension, Pulmonary; Incidence; Liver Diseases; Liver Function Tests; Male; Middle Aged; Risk Factors; Sex Factors; Sulfonamides; Treatment Outcome | 2006 |
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Endothelin A Receptor Antagonists; Epidemiologic Methods; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Cohort Studies; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Injections, Subcutaneous; Male; Middle Aged; Placebos; Sulfonamides; Survival Rate; Treatment Outcome | 2006 |
Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Sulfonamides; Vasodilator Agents | 2006 |
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Prospective Studies; Sulfonamides; Treatment Outcome | 2007 |
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study.
Topics: Acute Disease; Adaptation, Physiological; Adult; Altitude; Altitude Sickness; Arginine Vasopressin; Bosentan; Creatinine; Diuresis; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Female; Glomerular Filtration Rate; Humans; Hypertension, Pulmonary; Hypoxia; Kidney; Kidney Diseases; Male; Middle Aged; Muscle, Smooth, Vascular; Osmolar Concentration; Oxygen; Potassium Channels, Voltage-Gated; Pulmonary Artery; Pulmonary Edema; Receptors, Endothelin; Sulfonamides; Vasoconstriction | 2006 |
Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome; Vascular Resistance | 2006 |
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.
Topics: Administration, Inhalation; Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Sulfonamides; Vasodilator Agents | 2006 |
Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Lung; Middle Aged; Physical Endurance; Pilot Projects; Severity of Illness Index; Sulfonamides; Walking | 2006 |
Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Stroke Volume; Sulfonamides; Treatment Outcome; Vital Capacity | 2007 |
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Thiophenes; Treatment Outcome | 2007 |
Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Quality of Life; Sulfonamides | 2007 |
[Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Chronic Disease; Data Interpretation, Statistical; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2007 |
Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Bosentan; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2007 |
Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Bosentan; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Middle Aged; Quality of Life; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2007 |
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Topics: Administration, Oral; Adult; Aged; Bosentan; Brachial Artery; Dose-Response Relationship, Drug; E-Selectin; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Female; Humans; Hypertension, Pulmonary; Intercellular Adhesion Molecule-1; Male; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Ultrasonography; Vascular Endothelial Growth Factor A; Vasodilation | 2007 |
Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients.
Topics: Adult; Antihypertensive Agents; Blood Circulation; Blood Pressure; Bosentan; Epoprostenol; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Nitric Oxide; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Stroke Volume; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Heart Failure, Systolic; Humans; Hypertension, Pulmonary; Male; Severity of Illness Index; Sulfonamides; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left | 2008 |
Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonar
Topics: Aged; Antihypertensive Agents; Bosentan; Chronic Disease; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Pulmonary Embolism; Quality of Life; Severity of Illness Index; Sulfonamides | 2007 |
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Topics: Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Bosentan; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Drug Administration Schedule; Drug Therapy, Combination; Epidemiologic Methods; Female; Glucocorticoids; Humans; Hypertension, Pulmonary; Male; Middle Aged; Quality of Life; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2008 |
A randomised, controlled trial of bosentan in severe COPD.
Topics: Aged; Bosentan; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Hypoxia; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Sulfonamides; Vasodilator Agents | 2008 |
Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Middle Aged; Sulfonamides | 2000 |
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Exercise; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2001 |
Bosentan therapy for pulmonary arterial hypertension.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Liver; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Walking | 2002 |
428 other study(ies) available for bosentan anhydrous and Pulmonary Hypertension
| Article | Year |
|---|---|
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Topics: Animals; Dogs; Drug Design; Female; Half-Life; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Sildenafil Citrate; Structure-Activity Relationship; Substrate Specificity | 2019 |
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Disease Models, Animal; Hypertension, Pulmonary; Indazoles; Male; Monocrotaline; Nitriles; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilator Agents | 2022 |
Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report.
Topics: Bosentan; Counseling; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Arterial Hypertension; Receptors, Epoprostenol; Transaminases | 2022 |
[Evidence base for specific pulmonary vasodilators in adults with congenital heart disease].
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Randomized Controlled Trials as Topic; Vasodilator Agents | 2021 |
Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
Topics: Bosentan; Cost-Effectiveness Analysis; Humans; Hypertension, Pulmonary; Iran; Pulmonary Arterial Hypertension; Quality of Life | 2023 |
Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study.
Topics: Animals; Bosentan; Cross-Sectional Studies; Endothelin Receptor Antagonists; Female; Hypertension, Pulmonary | 2023 |
Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Molecular Docking Simulation; Pulmonary Arterial Hypertension; Rats; Sulfonamides | 2023 |
Reply to comment by Carratù P, et al. on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial.
Topics: Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sarcoidosis, Pulmonary | 2019 |
Comment on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial.
Topics: Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sarcoidosis, Pulmonary | 2019 |
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
Topics: Aged; Bosentan; Chronic Disease; Drug Therapy, Combination; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Walk Test | 2019 |
Presumed prenatal closure of foramen ovale and persistent pulmonary hypertension of the newborn.
Topics: Bosentan; Echocardiography; Female; Foramen Ovale; Heart Failure; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Pregnancy; Sildenafil Citrate; Treatment Outcome; Ultrasonography, Prenatal | 2020 |
Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan.
Topics: Bosentan; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Insurance Coverage; Japan; Phenylpropionates; Prevalence; Prognosis; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Universal Health Insurance | 2020 |
More than a rare cause of pulmonary hypertension in the elderly.
Topics: Aged, 80 and over; Bosentan; Computed Tomography Angiography; Coronary Vessel Anomalies; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Scimitar Syndrome; Sildenafil Citrate; Treatment Outcome | 2020 |
Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure.
Topics: Adolescent; Arterial Pressure; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Infant; Male; Retrospective Studies; Sildenafil Citrate; Treatment Outcome; United Kingdom; Vascular Resistance; Vasodilator Agents | 2020 |
[Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrimidines; Retrospective Studies; Russia; Sulfonamides; Treatment Outcome | 2020 |
Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Case-Control Studies; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Treatment Outcome; Ulcer | 2020 |
Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy.
Topics: Bosentan; Chronic Disease; Endarterectomy; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Artery; Pulmonary Embolism; Treatment Outcome | 2021 |
Atrial flutter regression in HIV-associated pulmonary arterial hypertension after treatment with bosentan.
Topics: Antihypertensive Agents; Atrial Flutter; Bosentan; Female; HIV Infections; Humans; Hypertension, Pulmonary; Middle Aged; Remission Induction; Treatment Outcome | 2016 |
Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pulmonary Veins; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2017 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Australia; Bosentan; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Treatment Failure; Young Adult | 2017 |
Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2017 |
Cardiopulmonary anomalies in incontinentia pigmenti patients.
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Incontinentia Pigmenti; Infant, Newborn; Oxygen Inhalation Therapy; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2018 |
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Prospective Studies; Pulmonary Wedge Pressure; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
Sildenafil-Bosentan Drug-Drug Interaction: A Word of Caution Regarding the Most Common Combination Therapy in Children with Advanced Pulmonary Arterial Hypertension.
Topics: Bosentan; Child; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Sildenafil Citrate | 2018 |
Bosentan Inducing Autoimmune Hepatitis in a Patient with Idiopathic Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Female; Hepatitis, Autoimmune; Humans; Hypertension, Pulmonary; Pulmonary Artery | 2018 |
Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Bosentan; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sildenafil Citrate; Treatment Outcome; Vasodilator Agents; Walking | 2018 |
Systemic sclerosis: severe pulmonary arterial hypertension and pericardial effusion at diagnosis.
Topics: Bosentan; Calcium Channel Blockers; Chest Pain; Diagnostic Errors; Diltiazem; Echocardiography; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Lung; Microscopic Angioscopy; Middle Aged; Pericardial Effusion; Pericarditis; Scleroderma, Systemic; Sulfonamides; Tomography, X-Ray Computed | 2018 |
Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Substitution; Echocardiography; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Prospective Studies; Pyridazines; Walk Test; Young Adult | 2018 |
Therapeutic monitoring response of pulmonary arterial hypertension using a combined computed tomography- computational fluid analysis strategy.
Topics: Aged; Antihypertensive Agents; Bosentan; Drug Monitoring; Fatal Outcome; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Tomography, X-Ray Computed | 2018 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
Definition and Management of Segmental Pulmonary Hypertension.
Topics: Bosentan; Cardiac Surgical Procedures; Disease Management; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Vascular Malformations | 2018 |
Initial experience with bosentan for the management of pulmonary hypertension after heart transplantation.
Topics: Antihypertensive Agents; Bosentan; Disease Management; Female; Follow-Up Studies; Heart Transplantation; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Right | 2018 |
CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Bosentan; Carbohydrate Sulfotransferases; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Polymorphism, Single Nucleotide; Sulfotransferases; Young Adult | 2018 |
Laparoscopic Rectopexy in a Patient With Pulmonary Hypertension Associated With Scleroderma: A Case Report.
Topics: Aged; Antihypertensive Agents; Bosentan; Female; Head-Down Tilt; Humans; Hypertension, Pulmonary; Laparoscopy; Preoperative Care; Rectal Prolapse; Tadalafil; Treatment Outcome | 2019 |
Hypoxia augments NaHS-induced ANP secretion via KATP channel, HIF-1α and PPAR-γ pathway.
Topics: 2-Methoxyestradiol; Anilides; Animals; Atrial Natriuretic Factor; Bosentan; Gene Expression Regulation; Glyburide; Heart Atria; Hydrogen Sulfide; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; KATP Channels; Male; Monocrotaline; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Organ Culture Techniques; Oxygen; Pinacidil; Potassium Channel Blockers; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfides | 2019 |
Smoking-related interstitial fibrosis (SRIF) and pulmonary hypertension.
Topics: Antihypertensive Agents; Biopsy; Bosentan; Carbolines; Cardiac Catheterization; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Fibrosis; Respiratory Function Tests; Smoking; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2013 |
Bosentan and antiretroviral therapy in an HIV/HBV/HCV coinfected Chinese patient with HIV-related pulmonary arterial hypertension.
Topics: Adult; Anti-HIV Agents; Bosentan; Familial Primary Pulmonary Hypertension; Hepacivirus; Hepatitis B virus; HIV; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2013 |
Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Incidence; Infant; Infant, Newborn; Male; Piperazines; Product Surveillance, Postmarketing; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; United States; United States Food and Drug Administration; Vasodilator Agents | 2013 |
Combination therapy in pulmonary arterial hypertension.
Topics: Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Hemodynamics; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Prostaglandins; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2013 |
Inflammatory responses of airway smooth muscle cells and effects of endothelin receptor antagonism.
Topics: Airway Remodeling; Bosentan; Chemokines; Endothelin Receptor Antagonists; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypertension, Pulmonary; Inflammation; Matrix Metalloproteinase 13; Myocytes, Smooth Muscle; Oligonucleotide Array Sequence Analysis; Phenylpropionates; Pulmonary Disease, Chronic Obstructive; Pyridazines; Receptors, Endothelin; RNA Stability; RNA, Messenger; Sulfonamides; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2013 |
Association of CYP2C9*2 with bosentan-induced liver injury.
Topics: Alanine Transaminase; Aryl Hydrocarbon Hydroxylases; Aspartate Aminotransferases; Bosentan; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Female; Genetic Association Studies; Genetic Markers; HEK293 Cells; Humans; Hypertension, Pulmonary; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters; Polymorphism, Single Nucleotide; Sulfonamides | 2013 |
Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Exercise Therapy; Exercise Tolerance; Female; Heart Failure; Hemodynamics; Histiocytosis, Langerhans-Cell; Humans; Hypertension, Pulmonary; Positron-Emission Tomography; Recovery of Function; Sulfonamides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Case 1: chronic thromboembolic pulmonary hypertension (CTEPH).
Topics: Adult; Anticoagulants; Antihypertensive Agents; Bosentan; Chronic Disease; Diuretics; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Pulmonary Embolism; Sulfonamides; Tomography, X-Ray Computed; Warfarin | 2013 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
Pulmonary hypertension complicating connective tissue disease.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Lung Transplantation; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pyridazines; Scleroderma, Systemic; Sulfonamides | 2013 |
Effectiveness of bosentan in a case of pulmonary arterial hypertension associated with myelodysplastic syndrome.
Topics: Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Myelodysplastic Syndromes; Sulfonamides; Treatment Outcome | 2014 |
Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy.
Topics: Aged; Antihypertensive Agents; Biomarkers; Bosentan; Endothelin-1; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nitric Oxide; Prospective Studies; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Diagnosis and treatment of pulmonary hypertension in infancy.
Topics: Bosentan; Bronchopulmonary Dysplasia; Hernia, Diaphragmatic; Humans; Hypertension, Pulmonary; Infant, Newborn; Milrinone; Nitric Oxide; Piperazines; Prostaglandins; Purines; Signal Transduction; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance | 2013 |
Recurrent gastrointestinal bleeding in a patient with Eisenmenger syndrome using bosentan.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Familial Primary Pulmonary Hypertension; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Pulmonary; Recurrence; Sulfonamides; Young Adult | 2013 |
Safety and tolerability of targeted therapies for pulmonary hypertension in children.
Topics: Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Longitudinal Studies; Male; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Norepinephrine; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasoconstriction | 2014 |
Managing the risk of drug-induced liver injury.
Topics: Aryl Hydrocarbon Hydroxylases; Bosentan; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2013 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension.
Topics: Bosentan; Cardiovascular Agents; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Fingers; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome | 2014 |
Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
Topics: Adolescent; Age Factors; Antihypertensive Agents; Bosentan; Child; Cohort Studies; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Netherlands; Piperazines; Purines; Secondary Care Centers; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Combined approach in ventricular septal defect and adult pulmonary hypertension.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Bosentan; Cardiac Surgical Procedures; Drug Therapy, Combination; Female; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Nitric Oxide; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2013 |
Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Hypertension, Pulmonary; Pyrimidines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Sulfonamides | 2014 |
Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Pulmonary Artery; Quinolines; Rats; Rats, Wistar; Sulfonamides; Urea; Urotensins | 2014 |
Repair of ventricular septal defect with Eisenmenger syndrome after bosentan treatment.
Topics: Antihypertensive Agents; Bosentan; Cardiac Surgical Procedures; Child; Eisenmenger Complex; Female; Heart Septal Defects, Ventricular; Heart Septum; Humans; Hypertension, Pulmonary; Sulfonamides; Time Factors; Treatment Outcome; Vascular Resistance | 2014 |
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pilot Projects; Piperazines; Prognosis; Purines; Registries; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2014 |
Unexpected pulmonary hypertensive crisis after surgery for ocular malignant melanoma.
Topics: Blood Pressure; Bosentan; Choroid Neoplasms; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Pulmonary Artery; Sulfonamides; Tomography, X-Ray Computed | 2014 |
Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis.
Topics: Adult; Antihypertensive Agents; Antineoplastic Agents; Autopsy; Benzamides; Bosentan; Cardiac Catheterization; Dyspnea; Echocardiography; Epoprostenol; Fatal Outcome; Hemangioma, Capillary; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Piperazines; Purines; Pyrimidines; Radiography, Thoracic; Sildenafil Citrate; Sulfonamides; Treatment Failure | 2014 |
Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
Topics: Bosentan; Carbon Dioxide; Endothelin Receptor Antagonists; Exercise; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen; Pulmonary Embolism; Sulfonamides; Ultrasonography; Vascular Resistance | 2014 |
Recovery from mitomycin-induced pulmonary arterial hypertension.
Topics: Antineoplastic Agents; Anus Neoplasms; Bosentan; Carcinoma; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Middle Aged; Mitomycin; Sulfonamides | 2014 |
Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension.
Topics: Asian People; Bosentan; Chronic Disease; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Time Factors | 2014 |
Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Heart Ventricles; Hypertension, Pulmonary; Inflammation; Male; Monocrotaline; Rats; Rats, Wistar; Sulfonamides | 2014 |
Plasma concentrations of tadalafil in children with pulmonary arterial hypertension.
Topics: Adolescent; Aging; Antihypertensive Agents; Bosentan; Carbolines; Child; Child, Preschool; Female; Humans; Hypertension, Pulmonary; Infant; Male; Sulfonamides; Tadalafil; Vasodilator Agents | 2014 |
Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arteriovenous Malformations; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Mutation; Pedigree; Piperazines; Pulmonary Artery; Pulmonary Veins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Bosentan as rescue treatment in refractory hypoxemia and pulmonary hypertension in a patient with ARDS and H7N9 influenza virus infection.
Topics: Antihypertensive Agents; Antiviral Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Hypoxia; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Positive-Pressure Respiration; Respiratory Distress Syndrome; Sulfonamides; Treatment Outcome | 2014 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.
Topics: Aged; Bosentan; Chemical and Drug Induced Liver Injury; Cholagogues and Choleretics; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Liver Function Tests; Middle Aged; Sulfonamides; Ursodeoxycholic Acid | 2014 |
Pulmonary hypertension due to fibrotic lung disease: hidden value in a neutral trial.
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Idiopathic Interstitial Pneumonias; Male; Sulfonamides | 2014 |
Bosentan treatment for pulmonary arterial hypertension due to patent ductus arteriosus and Down's syndrome in an infant.
Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Infant; Male; Sulfonamides; Treatment Outcome | 2014 |
Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Electrocardiography; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; New Zealand; Physical Examination; Piperazines; Practice Patterns, Physicians'; Purines; Respiratory Function Tests; Rheumatology; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Surveys and Questionnaires; Vasodilator Agents | 2014 |
Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Transplantation; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2014 |
Determination of the effects of pulmonary arterial hypertension and therapy on the cardiovascular system of rats by impedance cardiography.
Topics: Animals; Blood Pressure; Bosentan; Cardiography, Impedance; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin Receptor Antagonists; Heart Ventricles; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2014 |
[The management of adult female patients with Eisenmenger syndrome and advanced pulmonary arterial hypertension treatment: single center experience and follow-up for 5 years].
Topics: Adult; Antihypertensive Agents; Bosentan; Echocardiography; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Laser-Doppler Flowmetry; Piperazines; Pulmonary Wedge Pressure; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Turkey | 2014 |
Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down's syndrome.
Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Heart Septal Defects; Humans; Hypertension, Pulmonary; Infant; Male; Mitral Valve Insufficiency; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Atrial Septum; Bosentan; Cardiac Catheterization; Cardiac Surgical Procedures; Disease Management; Epoprostenol; Exercise Tolerance; Female; Heart Septal Defects, Atrial; Hemodynamics; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Sulfonamides; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2015 |
Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
Topics: Antihypertensive Agents; Arterial Pressure; Bosentan; Endothelin Receptor Antagonists; Female; Heart Failure; Heart-Assist Devices; Humans; Hypertension, Pulmonary; Male; Middle Aged; Missouri; Prosthesis Design; Pulmonary Artery; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
Efficacy of pulmonary vasodilator therapy in patients with functionally single ventricle.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Child; Child, Preschool; Endothelin Receptor Antagonists; Female; Fontan Procedure; Heart Ventricles; Humans; Hypertension, Pulmonary; Infant; Male; Retrospective Studies; Sulfonamides; Vasodilator Agents; Young Adult | 2015 |
Medical treatment for an adult patient with eisenmenger syndrome. A case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Eisenmenger Complex; Endothelin Receptor Antagonists; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Pyridazines; Sulfonamides | 2015 |
Eisenmenger syndrome with unrepaired patent ductus arteriosus.
Topics: Blood Transfusion; Bosentan; Diagnostic Imaging; Dobutamine; Ductus Arteriosus, Patent; Eisenmenger Complex; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Menorrhagia; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Tomography, X-Ray Computed; Vasodilator Agents; Young Adult | 2015 |
Bosentan in pulmonary hypertension secondary to unilateral absence of a pulmonary artery.
Topics: Adult; Angiography; Antihypertensive Agents; Bosentan; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Hypertension, Pulmonary; Pulmonary Artery; Sulfonamides | 2015 |
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prostaglandins; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance; Young Adult | 2015 |
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Cause of Death; Child; Connective Tissue Diseases; Drug Therapy, Combination; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Treatment Outcome; Vasodilator Agents; Young Adult | 2015 |
Comparison of angiogenic and proliferative effects of three commonly used agents for pulmonary artery hypertension (sildenafil, iloprost, bosentan): is angiogenesis always beneficial?
Topics: Angiogenesis Inducing Agents; Animals; Bosentan; Cell Proliferation; Chick Embryo; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Hypertension, Pulmonary; Iloprost; Sildenafil Citrate; Sulfonamides | 2015 |
Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
Topics: Antihypertensive Agents; Bosentan; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Echocardiography; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Male; Middle Aged; Phenylpropionates; Pyridazines; Sulfonamides; Treatment Outcome | 2015 |
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Longitudinal Studies; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Recovery of Function; Scleroderma, Systemic; Sulfonamides; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Pulmonary Artery; Pyrimidines; Rats, Wistar; Sulfonamides; Time Factors; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2015 |
Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2015 |
Bosentan-induced Reduction in Cyclosporine-A Levels: A Rare Interaction in an Infant With Osteopetrosis and Severe Pulmonary Hyperetension.
Topics: Antihypertensive Agents; Bosentan; Cyclosporine; Drug Interactions; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Infant; Male; Osteopetrosis; Sulfonamides | 2015 |
Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy.
Topics: Aged; Bosentan; Cohort Studies; Comorbidity; Female; Follow-Up Studies; France; Hemodynamics; Hospitals, University; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2015 |
Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents; Vital Capacity | 2015 |
Use of Pulmonary Hypertension Medications in Patients with Tetralogy of Fallot with Pulmonary Atresia and Multiple Aortopulmonary Collaterals.
Topics: Abnormalities, Multiple; Adolescent; Antihypertensive Agents; Bosentan; Catheterization; Child; Child, Preschool; District of Columbia; Echocardiography; Female; Hemodynamics; Hospitals, Pediatric; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Lung; Male; Phenylpropionates; Pulmonary Artery; Pulmonary Atresia; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tertiary Care Centers; Tetralogy of Fallot; Young Adult | 2016 |
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Topics: Bosentan; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Hypertension, Pulmonary; Limit of Detection; Phenylpropionates; Pyridazines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil; Tandem Mass Spectrometry | 2015 |
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Child, Preschool; Codon, Nonsense; Epoprostenol; Growth Differentiation Factor 2; Growth Differentiation Factors; Homozygote; Humans; Hypertension, Pulmonary; Male; Mexican Americans; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin | 2016 |
First data from Latvian chronic thromboembolic pulmonary hypertension registry.
Topics: Adult; Age Distribution; Aged; Anticoagulants; Bosentan; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Incidence; Latvia; Male; Middle Aged; Phenylpropionates; Prevalence; Pulmonary Embolism; Pyrazoles; Pyridazines; Pyridones; Registries; Rivaroxaban; Sex Distribution; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin; Young Adult | 2016 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Pharmacokinetics of drugs for pediatric pulmonary hypertension.
Topics: Administration, Oral; Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Infant; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Pulmonary Wedge Pressure; Sulfonamides; Tadalafil; Young Adult | 2016 |
Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia.
Topics: Antihypertensive Agents; Bosentan; Bronchopulmonary Dysplasia; Child, Preschool; Drug Therapy, Combination; Echocardiography; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Treatment Outcome | 2017 |
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Topics: Bosentan; Drug Design; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Rare Diseases; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Exercise Test; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Middle Aged; Physical Endurance; Prospective Studies; Sulfonamides; Treatment Outcome; Ventricular Function, Right | 2017 |
From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?
Topics: Adult; Antihypertensive Agents; Bosentan; Cohort Studies; Drug Substitution; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Pyrimidines; Sulfonamides | 2017 |
Pediatric Development of Bosentan Facilitated by Modeling and Simulation.
Topics: Adult; Body Weight; Bosentan; Child; Humans; Hypertension, Pulmonary; Models, Biological; Pediatrics; Sulfonamides | 2017 |
Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Topics: Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Phenylpropionates; Pulmonary Artery; Pyridazines; Pyrimidines; Radial Artery; Receptor, Endothelin A; Sulfonamides; Tissue Survival; Vasoconstriction | 2017 |
Endothelin-receptor antagonism: the future is bright.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides | 2008 |
Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Bronchopulmonary Dysplasia; Cardiac Catheterization; Child; Child, Preschool; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2008 |
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.
Topics: Animals; Bosentan; Cytochrome P-450 Enzyme System; Endothelin Receptor Antagonists; Gene Expression Regulation, Enzymologic; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Immunohistochemistry; Intramolecular Oxidoreductases; Lung; Male; Organ Size; Phenylpropionates; Pulmonary Artery; Pyridazines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides | 2008 |
[Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Endothelin-1; Fatal Outcome; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Scleroderma, Systemic; Sulfonamides | 2008 |
N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides | 2009 |
Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Cross-Sectional Studies; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Outcome Assessment, Health Care; Physical Endurance; Quality of Life; Retrospective Studies; Sulfonamides; Treatment Outcome; Walking | 2008 |
Treating pulmonary hypertension in COPD: where do we start?
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Sulfonamides; Vasodilator Agents | 2008 |
The responsiveness and validity of the CAMPHOR Utility Index.
Topics: Aged; Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Quality of Life; Reproducibility of Results; Severity of Illness Index; Sulfonamides; United Kingdom; Walking | 2008 |
Dramatic functional improvement following bariatric surgery in a patient with pulmonary arterial hypertension and morbid obesity.
Topics: Antihypertensive Agents; Bariatric Surgery; Bosentan; Continuous Positive Airway Pressure; Humans; Hypertension, Pulmonary; Lung; Male; Obesity, Morbid; Oxygen Inhalation Therapy; Sleep Apnea Syndromes; Sulfonamides; Treatment Outcome | 2008 |
[A case of severe pulmonary hypertension associated with COPD treated with epoprostenol].
Topics: Aged; Antihypertensive Agents; Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Male; Pulmonary Disease, Chronic Obstructive; Sulfonamides | 2008 |
Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Sulfonamides; Time Factors | 2008 |
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Antiretroviral Therapy, Highly Active; Bosentan; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Exercise Tolerance; Female; HIV Infections; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Sulfonamides; Treatment Outcome | 2009 |
Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?
Topics: Benzamides; Bosentan; Combined Modality Therapy; Continuous Positive Airway Pressure; Diuretics; Enteral Nutrition; Extracorporeal Membrane Oxygenation; Heart Failure; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Hypoxia; Iloprost; Imatinib Mesylate; Infant, Newborn; Male; Nitric Oxide; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.
Topics: Adolescent; Bosentan; Case-Control Studies; Child; Child, Preschool; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Kaplan-Meier Estimate; Lung Transplantation; Male; Nifedipine; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; United Kingdom; Vasodilator Agents | 2009 |
Bosentan in mild pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Sulfonamides | 2008 |
Bosentan in mild pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Severity of Illness Index; Sulfonamides; Vascular Resistance; Walking | 2008 |
Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Heart Ventricles; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Myocardial Contraction; Retrospective Studies; Sulfonamides; Treatment Outcome; Ultrasonography; Ventricular Function, Right; Walking | 2009 |
[Remarkable response of bosentan, an endothelin receptor antagonist, for a patient with Eisenmenger syndrome].
Topics: Aged; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Female; Heart Failure; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2008 |
Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.
Topics: Administration, Inhalation; Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Piperazines; Probability; Purines; Respiratory Function Tests; Retrospective Studies; Risk Assessment; Sarcoidosis; Severity of Illness Index; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Sulfones; Survival Rate; Treatment Outcome | 2009 |
Clinical practice: pulmonary hypertension in children.
Topics: Activin Receptors, Type II; Antigens, CD; Antihypertensive Agents; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Calcium Channel Blockers; Child; Electrocardiography; Endoglin; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Incidence; Piperazines; Point Mutation; Prevalence; Purines; Receptors, Cell Surface; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Portopulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Transplantation; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Tadalafil; Thiophenes; Treatment Outcome; Vasodilator Agents | 2010 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
Pulmonary hypertension therapy and COPD: still many questions to be answered.
Topics: Bosentan; Exercise; Humans; Hypertension, Pulmonary; Perfusion; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Pulmonary hypertension therapy and COPD: still many questions to be answered.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Research Design; Sulfonamides; Treatment Outcome | 2009 |
Pulmonary hypertension therapy and COPD: still many questions to be answered.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Research Design; Sulfonamides; Treatment Outcome | 2009 |
[Pulmonary hypertension in a patient on chronic hemodialysis].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Sjogren's Syndrome; Sulfonamides | 2009 |
Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bosentan; Connective Tissue Diseases; Disease Progression; Endothelial Cells; Endothelium, Vascular; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2009 |
Delayed hypersensitivity to bosentan.
Topics: Adult; Antihypertensive Agents; Betamethasone; Bosentan; Exanthema; Female; Glucocorticoids; Humans; Hypersensitivity, Delayed; Hypertension, Pulmonary; Lymphocyte Activation; Scleroderma, Systemic; Skin Tests; Sulfonamides | 2009 |
[Therapy of mild, but symptomatic pulmonary hypertension].
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides; Treatment Outcome; Vascular Resistance; Walking | 2009 |
The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan).
Topics: Animals; Bosentan; Connexin 43; Disease Models, Animal; Endothelin Receptor Antagonists; Gap Junctions; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Microscopy, Confocal; Microscopy, Electron; Monocrotaline; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Sulfonamides; Ventricular Remodeling | 2009 |
Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report.
Topics: Aged; Antihypertensive Agents; Bosentan; Female; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Severity of Illness Index; Sulfonamides; Time Factors | 2009 |
Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Drug Interactions; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Polypharmacy; Scleroderma, Systemic; Sulfonamides | 2009 |
Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Thiophenes; Transaminases; Treatment Outcome | 2009 |
Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Cytokines; Endothelin-1; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Interleukin-12; Male; Middle Aged; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides | 2009 |
Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan.
Topics: Antihypertensive Agents; Bosentan; Child; Humans; Hypertension, Portal; Hypertension, Pulmonary; Male; Portal Vein; Sulfonamides; Treatment Outcome | 2009 |
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Topics: Animals; Body Weight; Bosentan; Capillaries; Cyclic GMP-Dependent Protein Kinases; Diffusion; Endothelin Receptor Antagonists; Fibrosis; Hemodynamics; Hypertension, Pulmonary; In Vitro Techniques; Male; Mitochondria, Heart; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Myoglobin; Organ Size; Oxygen Consumption; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Sulfones; Ultrasonography | 2009 |
Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Probability; Quality of Life; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Severe pulmonary hypertension and adenotonsillectomy in a child with Trisomy-21 and obstructive sleep apnea.
Topics: Adenoidectomy; Anesthetics, Intravenous; Anticoagulants; Antihypertensive Agents; Bosentan; Child; Down Syndrome; Elective Surgical Procedures; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Intubation, Intratracheal; Piperazines; Piperidines; Propofol; Purines; Remifentanil; Severity of Illness Index; Sildenafil Citrate; Sleep Apnea, Obstructive; Sulfonamides; Sulfones; Tonsillectomy; Treatment Outcome; Vasodilator Agents; Warfarin | 2009 |
Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Immunologic Factors; Interferon beta-1b; Interferon-beta; Multiple Sclerosis; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2009 |
Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Biomarkers; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2009 |
Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Extremities; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome | 2009 |
Successful treatment of persistent pulmonary hypertension of the newborn with bosentan.
Topics: Antihypertensive Agents; Bosentan; Developing Countries; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Respiration, Artificial; Sulfonamides | 2009 |
Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Injections, Intravenous; Male; Middle Aged; Quality of Life; Sulfonamides; Treatment Outcome; Walking | 2009 |
Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Epoprostenol; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imatinib Mesylate; Liver Failure; Liver Transplantation; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome | 2009 |
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Costs and Cost Analysis; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Placebos; Purines; Pyridazines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Treatment Outcome | 2009 |
Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists?
Topics: Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sarcoidosis, Pulmonary; Sulfonamides | 2009 |
Efficacy of bosentan in the treatment of a patient with mixed connective tissue disease complicated by pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Dyspnea; Echocardiography; Female; Humans; Hypertension, Pulmonary; Mixed Connective Tissue Disease; Sulfonamides; Treatment Outcome | 2010 |
[Effectiveness of bosentan in the management of Latin American patients diagnosed with pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Colombia; Drug Evaluation; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2009 |
Pulmonary arterial hypertension and congenital heart disease: targeted therapies and operability.
Topics: Aged; Antihypertensive Agents; Bosentan; Child; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Recurrence; Sulfonamides | 2009 |
[Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Cell Proliferation; Endothelial Cells; Endothelin Receptor Antagonists; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Isoxazoles; Sulfonamides; Thiophenes; Vasoconstriction; Vasodilation | 2009 |
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Evaluation; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Test; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Piperazines; Purines; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2009 |
Safe treatment of pulmonary hypertension with bosentan in a patient with moyamoya disease and cerebral ischemia.
Topics: Antihypertensive Agents; Bosentan; Brain; Brain Ischemia; Calcium Channel Blockers; Cerebral Angiography; Cerebral Arteries; Cerebral Revascularization; Cerebrovascular Circulation; Child; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Moyamoya Disease; Receptors, Endothelin; Risk Assessment; Stroke; Sulfonamides; Treatment Outcome | 2010 |
Graves' disease associated with primary systemic sclerosis.
Topics: Azathioprine; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Graves Disease; Humans; Hypertension, Pulmonary; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Middle Aged; Mycophenolic Acid; Proteinuria; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2009 |
Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution.
Topics: Bosentan; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Pulmonary Edema; Pulmonary Medicine; Pulmonary Veno-Occlusive Disease; Purines; Risk; Sildenafil Citrate; Sulfonamides; Sulfones; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Unilateral absence of a left pulmonary artery: successful therapeutic response to a combination of bosentan and warfarin.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Diagnostic Imaging; Drug Therapy, Combination; Electrocardiography; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Artery; Sulfonamides; Warfarin | 2009 |
Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.
Topics: Analysis of Variance; Animals; Antibiotics, Antineoplastic; Antihypertensive Agents; Bleomycin; Bosentan; Collagen; Connective Tissue Growth Factor; Disease Models, Animal; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Physical Conditioning, Animal; Pulmonary Fibrosis; Rats; Rats, Wistar; Sulfonamides; Time Factors | 2010 |
The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Australia; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Registries; Sulfonamides; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.
Topics: Aged; Anti-Bacterial Agents; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fingers; Humans; Hypertension, Pulmonary; Liver Function Tests; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2010 |
[Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension].
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Male; Prospective Studies; Sulfonamides | 2009 |
The globalization of clinical trials in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2010 |
The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Phenotype; Receptors, Endothelin; Sulfonamides; Thiophenes | 2010 |
[Eisenmenger syndrome. Specific treatments].
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Life Expectancy; Male; Multicenter Studies as Topic; Palliative Care; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Sulfonamides | 2009 |
Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
Topics: Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Bosentan; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypertension, Pulmonary; International Normalized Ratio; Middle Aged; Pulmonary Embolism; Sulfonamides; Treatment Outcome; Warfarin | 2010 |
[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Practice Guidelines as Topic; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Cost Control; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension.
Topics: Acquired Immunodeficiency Syndrome; Arteries; Bosentan; Drug Interactions; Female; HIV Infections; Humans; Hypertension; Hypertension, Pulmonary; Middle Aged; Nevirapine; Plasma; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 2010 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian.
Topics: Aged, 80 and over; Amlodipine; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Digoxin; Dyspnea; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Sulfonamides; Warfarin | 2010 |
Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
Topics: Adult; Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Tolerance; Humans; Hypertension, Pulmonary; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2010 |
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Echocardiography; Endothelin Receptor Antagonists; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Lung; Myocardial Infarction; Prognosis; Rats; Sulfonamides | 2011 |
Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan.
Topics: Antihypertensive Agents; Bosentan; Dyspnea; Hemodynamics; Histiocytosis, Langerhans-Cell; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones | 2010 |
Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
Topics: Antihypertensive Agents; Bosentan; Female; Health Care Costs; Health Expenditures; Health Services; Humans; Hypertension, Pulmonary; Insurance Claim Review; Male; Managed Care Programs; Middle Aged; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; United States; Vasodilator Agents | 2010 |
Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Eisenmenger Complex; Epidemiologic Methods; Epoprostenol; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Pulmonary Artery; Sulfonamides; Treatment Outcome; Vascular Resistance; Young Adult | 2010 |
Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Connective Tissue Diseases; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Statistics as Topic; Sulfonamides; Thiophenes; Treatment Outcome | 2010 |
Hereditary hemorrhagic telangiectasia: rare cause of pulmonary hypertension?
Topics: Aged; Antihypertensive Agents; Bosentan; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2010 |
Pulmonary hypertension associated with use of phentermine.
Topics: Adult; Antihypertensive Agents; Bosentan; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Models, Chemical; Obesity; Phentermine; Radiography, Thoracic; Safety; Sulfonamides | 2010 |
Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Topics: 2-Methoxyestradiol; Animals; Antihypertensive Agents; Bosentan; Drug Synergism; Drug Therapy, Combination; Estradiol; Female; Hypertension, Pulmonary; Male; Monocrotaline; Muscle, Smooth, Vascular; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
[Efficacy of long-term oral monotherapy and additional effect of inhaled iloprost in patients with severe idiopathic pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Sulfonamides; Vasodilator Agents | 2010 |
Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Dyspnea; Endarterectomy; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Tomography, Spiral Computed | 2009 |
Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biomarkers, Pharmacological; Bosentan; Endothelin-1; Epoprostenol; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Sulfonamides; Time Factors; Treatment Outcome; Vascular Resistance; Young Adult | 2010 |
[PAH and many other indications. Old and new endothelin receptor antagonists.].
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Peptides; Sulfonamides | 2010 |
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
Topics: Antihypertensive Agents; Bosentan; Child; Connective Tissue Diseases; Disease Progression; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Retrospective Studies; Sulfonamides; Treatment Outcome | 2010 |
Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.
Topics: Bosentan; Exercise; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2010 |
[Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
Topics: Adult; Aged; Australia; Bosentan; Cooperative Behavior; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Piperazines; Prospective Studies; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Young Adult | 2011 |
Sinus venosus atrial septal defect in a 31-year-old female patient: a case for surgical repair.
Topics: Adult; Antihypertensive Agents; Bosentan; Echocardiography, Transesophageal; Female; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Sulfonamides; Treatment Outcome | 2010 |
Pulmonary arterial hypertension: combination therapy in the modern management era.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2010 |
Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension.
Topics: Acetylcholine; Aged; Antihypertensive Agents; Arginine; Bosentan; Endothelium, Vascular; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Nitroprusside; omega-N-Methylarginine; Pulmonary Artery; Sulfonamides; Ultrasonography | 2010 |
Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Bosentan; Echocardiography, Doppler; Endothelin Receptor Antagonists; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Recovery of Function; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Bosentan - a previously unrecognised cause of facial telangiectasia.
Topics: Aged; Antihypertensive Agents; Bosentan; Endothelin-1; Face; Female; Humans; Hypertension, Pulmonary; Sulfonamides; Telangiectasis | 2010 |
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children.
Topics: Adolescent; Algorithms; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Disease Progression; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pulmonary Medicine; Retrospective Studies; Sulfonamides; Treatment Outcome | 2011 |
The pressure wire as a diagnostic tool in patients with congenital cardiac disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Dyspnea; Female; Heart Defects, Congenital; Heart Valve Prosthesis; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Sulfonamides; Young Adult | 2011 |
The rise and fall of endothelin receptor antagonists in congestive heart failure.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiology; Disease Models, Animal; Endothelin Receptor Antagonists; Heart; Heart Failure; Humans; Hypertension, Pulmonary; Myocardium; Prognosis; Sulfonamides | 2011 |
[Using nonselective endothelin receptor antagonist in idiopathic pulmonary hypertension].
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2010 |
Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
Topics: Adolescent; Age Factors; Aryl Hydrocarbon Hydroxylases; Asian People; Bayes Theorem; Body Weight; Bosentan; Child; Child, Preschool; Computer Simulation; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Familial Primary Pulmonary Hypertension; Female; Genotype; Heart Failure; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Liver-Specific Organic Anion Transporter 1; Male; Models, Biological; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperazines; Polymorphism, Single Nucleotide; Purines; Sildenafil Citrate; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Sulfones | 2011 |
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Muscle, Smooth, Vascular; Nifedipine; Nitric Oxide Synthase Type III; Piperazines; Pulmonary Artery; Purines; Receptor, Endothelin A; Receptor, Endothelin B; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2011 |
Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Germany; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Propensity Score; Proportional Hazards Models; Pulmonary Artery; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; Waiting Lists | 2012 |
Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.
Topics: Bosentan; Canada; Epoprostenol; Europe; Health Surveys; Humans; Hypertension, Pulmonary; Iloprost; Methotrexate; North America; Practice Guidelines as Topic; Scleroderma, Systemic; Skin Diseases; Societies, Medical; Sulfonamides; Treatment Outcome; Vascular Diseases | 2011 |
[Tuberculous tenosynovitis].
Topics: Aged; Anti-Inflammatory Agents; Antihypertensive Agents; Antitubercular Agents; Bosentan; Combined Modality Therapy; CREST Syndrome; Diagnosis, Differential; Female; Hand; Humans; Hypertension, Pulmonary; Opportunistic Infections; Sulfonamides; Tenosynovitis; Tuberculosis, Osteoarticular | 2011 |
Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Collagen; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Myocardium; Protein Isoforms; Protein Kinase C; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfonamides; Ventricular Dysfunction, Right | 2011 |
Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.
Topics: Acid-Base Equilibrium; Aged; Antihypertensive Agents; Blood Gas Analysis; Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Oxygen Inhalation Therapy; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Thromboembolism; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2013 |
Late clinical manifestations of mitral valve disease and severe pulmonary hypertension in a patient diagnosed with premature closure of foramen ovale during fetal life.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Fetal Diseases; Foramen Ovale; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Mitral Valve Stenosis; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Failure; Ultrasonography, Doppler, Pulsed; Ultrasonography, Prenatal; Vasodilator Agents | 2011 |
Constrictive-like physiology in severe pulmonary hypertension: the effect of the Valsalva maneuver.
Topics: Adult; Antihypertensive Agents; Bosentan; Constriction, Pathologic; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Sulfonamides; Ultrasonography; Valsalva Maneuver | 2011 |
[Successful bosentan therapy in a case of pulmonary arterial hypertention developed during immunosuppressive therapy for lupus nephritis].
Topics: Adult; Antihypertensive Agents; Bosentan; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Prednisolone; Sulfonamides; Treatment Outcome | 2011 |
Transcatheter intervention following bosentan-iloprost treatment in a patient with patent ductus arteriosus and pulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Ductus Arteriosus, Patent; Female; Humans; Hypertension, Pulmonary; Iloprost; Septal Occluder Device; Sulfonamides; Vasodilator Agents | 2012 |
Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Child; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Mesentery; Middle Aged; Piperazines; Purines; Regional Blood Flow; Renal Veins; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Splenic Vein; Sulfonamides; Sulfones; Tomography, Spiral Computed; Treatment Outcome; Vena Cava, Inferior | 2011 |
Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Survival Rate; Time Factors | 2013 |
[Treatment of idiopathic pulmonary arterial hypertension].
Topics: Adult; Airway Resistance; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Lung Volume Measurements; Male; Middle Aged; Oxygen Consumption; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Retrospective Studies; Sulfonamides; Young Adult | 2013 |
Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Child; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Pulmonary Wedge Pressure; Scleroderma, Systemic; Sulfonamides; Thermography; Vascular Resistance | 2011 |
Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries.
Topics: Aged; Antihypertensive Agents; Autocrine Communication; Bosentan; Cell Division; Cells, Cultured; Humans; Hypertension, Pulmonary; MAP Kinase Signaling System; Middle Aged; Muscle, Smooth, Vascular; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Receptor, Endothelin A; Receptor, Endothelin B; rhoA GTP-Binding Protein; Smoking; Sulfonamides; Up-Regulation; Vasoconstriction | 2012 |
Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope.
Topics: Adult; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Hypertension, Portal; Hypertension, Pulmonary; Male; Monitoring, Physiologic; Pulmonary Wedge Pressure; Sulfonamides; Syncope | 2011 |
Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dermatologic Agents; Female; Foot Ulcer; Humans; Hypertension, Pulmonary; Middle Aged; Off-Label Use; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Wound Healing | 2012 |
Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Topics: Adult; Aged; Alanine Transaminase; Antihypertensive Agents; Aspartate Aminotransferases; Bosentan; Down Syndrome; Exercise Tolerance; Female; Heart Defects, Congenital; Hemoglobins; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen; Retrospective Studies; Sex Factors; Sulfonamides | 2011 |
Pulmonary hypertension presenting with apnea, cyanosis, and failure to thrive in a young child.
Topics: Antihypertensive Agents; Apnea; Biopsy; Bosentan; Cyanosis; Failure to Thrive; Familial Primary Pulmonary Hypertension; Fatal Outcome; Female; Hemangioma, Capillary; Humans; Hypertension, Pulmonary; Infant; Lung; Lung Neoplasms; Radiography, Thoracic; Sulfonamides | 2011 |
Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Pulmonary Emphysema; Sulfonamides; Vasodilator Agents | 2011 |
Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Carbolines; Cardiac Output; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography; Electrocardiography; Epoprostenol; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Middle Aged; Sulfonamides; Tadalafil; Vasodilator Agents | 2011 |
VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.
Topics: Animals; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Monocrotaline; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides; Vasoactive Intestinal Peptide | 2011 |
Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allergy and Immunology; Bosentan; Cardiac Catheterization; Cardiology; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Kaplan-Meier Estimate; Male; Mass Screening; Middle Aged; Outpatient Clinics, Hospital; Patient Care Team; Piperazines; Prospective Studies; Pulmonary Medicine; Purines; Rheumatology; Sildenafil Citrate; Sulfonamides; Sulfones; Tertiary Care Centers; Ultrasonography; Young Adult | 2013 |
Successful shunt closure and improvement of hemodynamics in an ASD patient with severe pulmonary arterial hypertension and small shunt following a long-term use of bosentan.
Topics: Adult; Bosentan; Drug Administration Schedule; Female; Heart Septal Defects, Atrial; Hemodynamics; Humans; Hypertension, Pulmonary; Severity of Illness Index; Sulfonamides; Treatment Outcome; Ultrasonography | 2012 |
Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.
Topics: Adult; Algorithms; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Hospitals, Pediatric; Humans; Hypertension, Pulmonary; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prevalence; Pyridazines; Sulfonamides; Texas; Transition to Adult Care | 2011 |
The management of Eisenmenger syndrome in the modern treatment era: a case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Drug Therapy, Combination; Eisenmenger Complex; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Iron, Dietary; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
"Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Topics: Adult; Antihypertensive Agents; Bosentan; Case-Control Studies; Drug Therapy, Combination; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Injections, Intravenous; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2012 |
Chronic thromboembolic pulmonary hypertension due to upper-extremity deep vein thrombosis caused by thoracic outlet syndrome.
Topics: Antihypertensive Agents; Arm; Asthma; Bosentan; Cardiac Catheterization; Dyspnea; Female; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Smoking; Sulfonamides; Syncope; Thoracic Outlet Syndrome; Thrombophlebitis; Young Adult | 2012 |
Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach.
Topics: Adult; Algorithms; Anticoagulants; Antihypertensive Agents; Bosentan; Enoxaparin; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Postnatal Care; Pregnancy; Pregnancy Complications, Cardiovascular; Prenatal Care; Sulfonamides; Young Adult | 2012 |
Thrombotic microangiopathic nephropathy, pulmonary hypertension and nephromegaly: case report of a patient treated with endothelin receptor antagonist.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Kidney; Male; Sulfonamides; Thrombotic Microangiopathies | 2012 |
Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bosentan; Endothelin-1; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome | 2013 |
Pulmonary arterial hypertension during systemic lupus.
Topics: Adult; Bosentan; Cyclophosphamide; Familial Primary Pulmonary Hypertension; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Middle Aged; Mycophenolic Acid; Steroids; Sulfonamides; Treatment Outcome | 2012 |
Curing HIV-associated pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; HIV Infections; Humans; Hypertension, Pulmonary; Middle Aged; Remission Induction; Sulfonamides | 2012 |
Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Female; Hypertension, Pulmonary; Iloprost; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2012 |
Abnormal pulmonary artery stiffness in pulmonary arterial hypertension: in vivo study with intravascular ultrasound.
Topics: Aged; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Wedge Pressure; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional; Vascular Stiffness | 2012 |
Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Cohort Studies; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Pyridazines; Retrospective Studies; Sulfonamides | 2013 |
Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2012 |
A case of portopulmonary hypertension spanning 18 years: successful use of bosentan for progressive disease after two liver transplantations.
Topics: Bosentan; Disease Progression; Female; Humans; Hypertension, Pulmonary; Hypertension, Renal; Liver Transplantation; Middle Aged; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension; Hypertension, Pulmonary; Male; Middle Aged; Portal System; Retrospective Studies; Sulfonamides | 2013 |
Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sulfonamides; Thiophenes; Treatment Outcome; Vascular Resistance | 2013 |
Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Drug Interactions; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Receptor, Endothelin B; Sulfonamides | 2012 |
Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; beta-Thalassemia; Bosentan; Female; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Artery; Sulfonamides | 2012 |
Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
Topics: Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Sulfonamides; Thiophenes; Vascular Resistance | 2013 |
Bosentan reduces pulmonary artery pressure in high altitude residents.
Topics: Adult; Aged; Altitude; Antihypertensive Agents; Bosentan; Case-Control Studies; Echocardiography; Endothelin-1; Female; Gene Frequency; Genotype; Humans; Hypertension, Pulmonary; Male; Middle Aged; Polymorphism, Genetic; Pulmonary Artery; Sulfonamides | 2012 |
Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device.
Topics: Antihypertensive Agents; Bosentan; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2013 |
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Topics: Animals; Bosentan; Calcium; CHO Cells; Clinical Trials, Phase III as Topic; Cricetinae; Endothelin Receptor Antagonists; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Inositol Phosphates; Myocytes, Smooth Muscle; Phenylpropionates; Pulmonary Artery; Pyridazines; Pyrimidines; Receptors, Endothelin; Sulfonamides | 2012 |
Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.
Topics: Animals; Bosentan; Disease Models, Animal; Female; Hypertension, Pulmonary; Nitrates; Nitrosation; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sulfonamides | 2013 |
Adult congenital heart disease and pulmonary hypertension: management of a complex case.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Dyspnea; Eisenmenger Complex; Exercise Test; Follow-Up Studies; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Oxygen; Pulmonary Valve Stenosis; Sulfonamides | 2012 |
Has the 6-min walk distance run its course?
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Sulfonamides | 2012 |
Efficacy of right ventricular free-wall longitudinal speckle-tracking strain for predicting long-term outcome in patients with pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Epoprostenol; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Predictive Value of Tests; Prognosis; ROC Curve; Sensitivity and Specificity; Sulfonamides; Vasodilator Agents; Ventricular Dysfunction, Right | 2013 |
Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Exercise Test; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Transplantation; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Sulfonamides; Vasodilator Agents | 2013 |
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2012 |
Pulmonary hypertension in COPD.
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Bosentan; Comorbidity; Coronary Artery Disease; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Sulfonamides; Treatment Outcome; Vasoconstriction; Vasoconstrictor Agents | 2013 |
Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
Topics: Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Fingers; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vascular Diseases | 2013 |
Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Prospective Studies; Sulfonamides; Time Factors | 2013 |
Bosentan for pulmonary hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Dyspnea; Exercise Tolerance; Humans; Hypertension, Pulmonary; Pulmonary Artery; Sulfonamides | 2002 |
Bosentan for pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Liver; Sulfonamides; Transaminases | 2002 |
Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
Topics: Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Hypertension, Pulmonary; Ischemia; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2003 |
[Young patient with stress dyspnea of uncertain origin. Evaluate for pulmonary hypertension!].
Topics: Adult; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Diagnosis, Differential; Dyspnea; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Male; Physical Exertion; Sulfonamides | 2002 |
Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Lung; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2003 |
Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelial Growth Factors; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hemodynamics; Hypertension, Pulmonary; Intercellular Signaling Peptides and Proteins; Lung; Lymphokines; Myocardium; Nitric Oxide; Pulmonary Artery; Pulmonary Circulation; RNA, Messenger; Sulfonamides; Swine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Treatment of pulmonary arterial hypertension: a step forward.
Topics: Antihypertensive Agents; Bosentan; Endothelin-1; Epoprostenol; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Sulfonamides | 2003 |
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Topics: Adult; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Time Factors | 2003 |
[Blockade of endothelin receptor with bosentan--a new principle of treatment in pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Controlled Clinical Trials as Topic; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sulfonamides | 2003 |
Expression of the serotonin 1b receptor in experimental pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Carrier Proteins; Hypertension, Pulmonary; Lung; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Polymerase Chain Reaction; Pulmonary Circulation; Receptor, Serotonin, 5-HT1B; Receptors, Endothelin; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sulfonamides; Swine | 2003 |
[Dyspnea. When is it pulmonary hypertension?].
Topics: Antihypertensive Agents; Bosentan; Diagnosis, Differential; Dyspnea; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides | 2003 |
Bosentan for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Costs; Humans; Hypertension, Pulmonary; Liver; Randomized Controlled Trials as Topic; Sulfonamides | 2003 |
Bosentan and overcirculation-induced experimental pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Hypertension; Hypertension, Pulmonary; Models, Animal; Pulmonary Circulation; Sulfonamides; Swine | 2003 |
New combined treatments avoided transplantation in a child with severe pulmonary hypertension.
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Child; Drug Therapy, Combination; Echocardiography; Humans; Hypertension, Pulmonary; Iloprost; Male; Sulfonamides; Vasodilator Agents | 2004 |
Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Humans; Hypertension, Pulmonary; Isoxazoles; Sulfonamides; Thiophenes | 2004 |
Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
Topics: Adult; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Kidney Failure, Chronic; Scleroderma, Systemic; Sulfonamides | 2004 |
Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Male; Sulfonamides | 2004 |
Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan.
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Transplantation; Middle Aged; Sulfonamides; Treatment Outcome | 2004 |
New answers raise new questions in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Endpoint Determination; Humans; Hypertension, Pulmonary; Pulmonary Artery; Randomized Controlled Trials as Topic; Sulfonamides | 2004 |
[Bosentán, hope or reality for the treatment of pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Sulfonamides | 2004 |
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; HIV Infections; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Pulmonary Artery; Sulfonamides; Treatment Outcome | 2004 |
Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes.
Topics: Animals; Blotting, Western; Bosentan; Calcium Channel Blockers; Calcium Channels; Cell Proliferation; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Hypertension, Pulmonary; Male; Myocytes, Smooth Muscle; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Reference Values; Sampling Studies; Sensitivity and Specificity; Sulfonamides; Up-Regulation | 2004 |
Severe necrotising leucocytoclastic vasculitis in a patient taking bosentan.
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Middle Aged; Sulfonamides; Vasculitis, Leukocytoclastic, Cutaneous | 2004 |
Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Long-Term Care; Male; Middle Aged; Substance Withdrawal Syndrome; Sulfonamides; Treatment Outcome | 2004 |
Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Cirrhosis; Liver Transplantation; Middle Aged; Platelet Aggregation Inhibitors; Sulfonamides; Time Factors | 2004 |
Endothelin-receptor antagonist treatment of portopulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Female; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Middle Aged; Sulfonamides | 2004 |
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2004 |
[Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Physical Endurance; Pilot Projects; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2004 |
Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis, Alcoholic; Male; Sulfonamides; Treatment Outcome | 2005 |
[Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
Topics: Administration, Oral; Algorithms; Antihypertensive Agents; Bosentan; Echocardiography; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Time Factors; Walking | 2004 |
Improving survival in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Prognosis; Randomized Controlled Trials as Topic; Registries; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Bosentan therapy for portopulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Oxygen Consumption; Retrospective Studies; Sulfonamides; Treatment Outcome | 2005 |
[Bosentan].
Topics: Antihypertensive Agents; Bosentan; Contraindications; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides | 2005 |
[New choice of therapy of pulmonary hypertension: endothelin receptor antagonist].
Topics: Adult; Atrasentan; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyrimidines; Pyrrolidines; Sulfonamides | 2005 |
Resolution of severe digital ulceration during a course of Bosentan therapy.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2005 |
Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy.
Topics: Adult; Antihypertensive Agents; Bosentan; Breath Tests; Case-Control Studies; Exhalation; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nitric Oxide; Pulmonary Artery; Respiratory Function Tests; Sulfonamides | 2005 |
Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
Topics: Administration, Inhalation; Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Monitoring, Ambulatory; Prostheses and Implants; Sulfonamides | 2005 |
Pulmonary arterial hypertension: the race for the most effective treatment.
Topics: Antihypertensive Agents; Bosentan; Drug Evaluation; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
[Pulmonary hypertension in hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease). Progression over 10 years].
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Diuretics; Endothelin Receptor Antagonists; Epistaxis; Epoprostenol; Female; Furosemide; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Nifedipine; Pedigree; Phenprocoumon; Pyridines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic; Treatment Failure; Vasodilator Agents | 2005 |
Eisenmenger syndrome in the adult--experience with new drugs for the treatment of pulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Retrospective Studies; Sulfonamides; Vasodilator Agents | 2005 |
Severe left ventricular dysfunction secondary to primary pulmonary hypertension: bridging therapy with bosentan before lung transplantation.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Humans; Hypertension, Pulmonary; Lung Transplantation; Male; Severity of Illness Index; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2005 |
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Area Under Curve; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2005 |
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
Topics: Adult; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Assessment; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Pulmonary hypertension: its diagnosis and management, a multidisciplinary approach.
Topics: Adult; Algorithms; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Middle Aged; Respiratory Function Tests; Sulfonamides | 2005 |
[PAH in congenital heart defects--therapeutic experiences with children and adults].
Topics: Antihypertensive Agents; Bosentan; Child; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Defects, Congenital; Heart Septal Defects; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome; Vascular Resistance | 2005 |
A urinary test for pulmonary arterial hypertension?
Topics: Antihypertensive Agents; Arginine; Bosentan; Humans; Hypertension, Pulmonary; Nitric Oxide; Pulmonary Artery; Sulfonamides | 2005 |
Bosentan in inoperable chronic thromboembolic pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Sulfonamides; Thromboembolism | 2005 |
Effects of long-term bosentan in children with pulmonary arterial hypertension.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Prostaglandins; Retrospective Studies; Risk Assessment; Risk Factors; Safety; Sulfonamides; Survival Analysis; Time; Treatment Outcome | 2005 |
Improving the outcome of childhood pulmonary arterial hypertension: the effect of bosentan in the setting of a dedicated pulmonary hypertension clinic.
Topics: Antihypertensive Agents; Bosentan; Child; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2005 |
Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Liver Cirrhosis, Alcoholic; Male; Recurrence; Sulfonamides; Time Factors | 2005 |
[Course of pulmonary artery hypertension disease].
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Endothelin-1; Humans; Hypertension, Pulmonary; Pilot Projects; Prognosis; Randomized Controlled Trials as Topic; Sulfonamides | 2005 |
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Exercise Tolerance; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Recovery of Function; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Response to bosentan in children with pulmonary hypertension.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infant; Male; Retrospective Studies; Sulfonamides; Treatment Outcome | 2006 |
[A role for combination therapy in pulmonary arterial hypertension].
Topics: Administration, Inhalation; Antihypertensive Agents; Bosentan; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2005 |
Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin-1; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Respiratory Function Tests; Sarcoidosis, Pulmonary; Sulfonamides | 2008 |
Improving survival in idiopathic pulmonary arterial hypertension: revisiting the "kingdom of the near-dead".
Topics: Antihypertensive Agents; Bosentan; Forecasting; Humans; Hypertension, Pulmonary; Prognosis; Sulfonamides; Survival Analysis | 2005 |
Possible reduction in indinavir serum concentrations by bosentan.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Bosentan; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hypertension, Pulmonary; Indinavir; Male; Metabolic Clearance Rate; Sulfonamides | 2005 |
PHARMAC not funding some treatments for rare, life-threatening diseases: bosentan as an example.
Topics: Antihypertensive Agents; Bosentan; Drug Approval; Health Policy; Humans; Hypertension, Pulmonary; National Health Programs; New Zealand; Sulfonamides | 2005 |
Treatment of pulmonary hypertension secondary to alveolar microlithiasis with Bosentan: a case report.
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Lithiasis; Lung Diseases; Middle Aged; Sulfonamides | 2005 |
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Prostaglandins; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Vasodilator Agents | 2006 |
Functional and metabolic recovery of the right ventricle during Bosentan therapy in idiopathic pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Magnetic Resonance Spectroscopy; Male; Middle Aged; Phosphates; Pulmonary Wedge Pressure; Stroke Volume; Sulfonamides; Ventricular Dysfunction, Right; Ventricular Function, Right | 2005 |
PHARMAC responds on treatments for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Drug Approval; Humans; Hypertension, Pulmonary; National Health Programs; New Zealand; Sulfonamides | 2005 |
Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
Topics: Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Pulmonary Wedge Pressure; Receptors, Endothelin; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Sulfonamides; Thromboembolism | 2005 |
Bosentan in pulmonary arterial hypertension secondary to scleroderma.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Respiratory Function Tests; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease-Free Survival; Drug Therapy, Combination; Exercise Test; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Liver; Male; Middle Aged; Platelet Aggregation Inhibitors; Prostaglandins; Retrospective Studies; Sulfonamides; Treatment Outcome | 2006 |
Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.
Topics: Adult; Bosentan; Cardiac Catheterization; Cohort Studies; Digoxin; Drug Administration Routes; Epoprostenol; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Transplantation; Male; Pulmonary Circulation; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sulfonamides; Survival Analysis; Treatment Outcome; Vasodilation; Warfarin | 2006 |
Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Middle Aged; Patient Selection; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2006 |
[Endothelin receptor antagonism in routine clinical care].
Topics: Bosentan; Controlled Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Prognosis; Scleroderma, Systemic; Sulfonamides; Survival Analysis | 2005 |
Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension.
Topics: Age Factors; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Disease Progression; Female; Humans; Hypertension, Pulmonary; Male; Sulfonamides; Survival Analysis | 2006 |
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Bosentan; Disease Progression; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Sulfonamides; Thromboembolism; Time Factors; Treatment Outcome | 2006 |
Bosentan may induce arthritis flare in patients with scleroderma concomitantly treated with methotrexate.
Topics: Antihypertensive Agents; Arthritis; Bosentan; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2006 |
Persistent painful indurated erythema secondary to bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Erythema; Female; Humans; Hypertension, Pulmonary; Pain; Sulfonamides; Ventricular Dysfunction, Right | 2006 |
Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats.
Topics: Angiotensinogen; Animals; Antihypertensive Agents; Bosentan; Cytochrome P-450 CYP11B2; Endothelin-1; Gene Expression Regulation; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Male; Monocrotaline; Myocardial Contraction; Natriuretic Peptide, Brain; Neurotransmitter Agents; Peptides, Cyclic; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides; Ventricular Function; Ventricular Remodeling | 2006 |
Long-term bosentan treatment in children with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Child; Dosage Forms; Humans; Hypertension, Pulmonary; Sulfonamides | 2006 |
Long-term bosentan in chronic thromboembolic pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Exercise Tolerance; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Prospective Studies; Sulfonamides; Thromboembolism; Treatment Outcome; Ventricular Function, Right | 2007 |
Drug-related hepatotoxicity.
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides; Transaminases | 2006 |
Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Pulmonary Wedge Pressure; Retrospective Studies; Sulfonamides; Treatment Outcome | 2006 |
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Topics: Animals; Bosentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
Drug eruption due to bosentan in a patient with systemic sclerosis.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Drug Eruptions; Endothelin Receptor Antagonists; Eosinophilia; Female; Humans; Hypertension, Pulmonary; Middle Aged; Prednisolone; Scleroderma, Systemic; Sulfonamides | 2006 |
Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Antiretroviral Therapy, Highly Active; Bosentan; Drug Combinations; Exercise Test; Female; HIV Infections; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2006 |
Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Ductus Arteriosus, Patent; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides | 2007 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Disease Management; Drug Interactions; Endothelin Receptor Antagonists; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents; Walking | 2006 |
Dual endothelin receptor antagonism in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides | 2006 |
Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Drug Therapy, Combination; Exercise Test; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prostaglandins, Synthetic; Pulmonary Circulation; Retrospective Studies; Sulfonamides; Treatment Outcome; Vascular Resistance; Walking | 2006 |
First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Test; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pulmonary Fibrosis; Scleroderma, Systemic; Sulfonamides; Walking | 2006 |
Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Connective Tissue Diseases; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Mixed Connective Tissue Disease; Myositis; Prospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Right; Walking | 2006 |
Successful treatment of portopulmonary hypertension with bosentan: case report.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Echocardiography; Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis, Alcoholic; Male; Sulfonamides; Treatment Outcome; Vasodilation | 2006 |
Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Hepatitis C, Chronic; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Male; Sulfonamides; Treatment Outcome | 2006 |
Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Treatment Outcome | 2006 |
Bosentan therapy for pulmonary arterial hypertension associated with hereditary haemorrhagic telangiectasia.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Middle Aged; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic; Treatment Outcome | 2006 |
Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors | 2006 |
[Transition from prostacyclin to bosentan in five patients with severe pulmonary hypertension: the switch is possible].
Topics: Adult; Antihypertensive Agents; Bosentan; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Severity of Illness Index; Sulfonamides | 2006 |
Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.
Topics: Antihypertensive Agents; Australia; Bosentan; Cost-Benefit Analysis; Economics, Pharmaceutical; Financing, Government; Humans; Hypertension, Pulmonary; Lung Transplantation; Models, Economic; Registries; Risk Sharing, Financial; Sulfonamides; Survival Rate | 2006 |
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
Topics: Adult; Antihypertensive Agents; Bosentan; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Male; Renal Insufficiency; Sulfonamides; Treatment Outcome | 2006 |
Bosentan improves functional class, pulmonary artery systolic pressure, and DLCO in scleroderma patients with pulmonary hypertension: a possible synergy with iloprost.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Respiratory Function Tests; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target?
Topics: Altitude; Altitude Sickness; Bosentan; Diuresis; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Hypoxia; Kidney Diseases; Muscle, Smooth, Vascular; Potassium Channels, Voltage-Gated; Randomized Controlled Trials as Topic; Receptors, Endothelin; Sulfonamides; Vasoconstriction; Ventricular Function, Right | 2006 |
Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia.
Topics: Antihypertensive Agents; Bosentan; Bronchopulmonary Dysplasia; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infant, Newborn; Severity of Illness Index; Sulfonamides | 2006 |
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Volume Measurements; Male; Middle Aged; Piperazines; Pulmonary Wedge Pressure; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Heart Transplantation; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Waiting Lists | 2006 |
Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Eisenmenger Complex; Exercise Tolerance; Female; Heart Rate; Humans; Hypertension, Pulmonary; Long-Term Care; Male; Oxygen Consumption; Prospective Studies; Sulfonamides; Treatment Outcome; Vascular Resistance | 2007 |
[Long-term outcomes of treatment with bosentan in pulmonary hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
Topics: Antihypertensive Agents; Bosentan; Child; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Lung Transplantation; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
Bosentan improved syncope in a hemodialysis patient with pulmonary hypertension and mild aortic stenosis.
Topics: Aged; Antihypertensive Agents; Aortic Valve Stenosis; Bosentan; Female; Humans; Hypertension, Pulmonary; Renal Dialysis; Sulfonamides; Syncope | 2006 |
The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Bosentan; Diltiazem; Epoprostenol; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Sulfonamides; Survival Rate; Treatment Outcome; Vasodilator Agents | 2007 |
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
[Pulmonary hypertension treatment: future prospects].
Topics: Administration, Intranasal; Administration, Oral; Animals; Bosentan; Drug Evaluation, Preclinical; Endothelin A Receptor Antagonists; Epoprostenol; Forecasting; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Isoxazoles; Life Expectancy; Lung Transplantation; Monocrotaline; Piperazines; Platelet-Derived Growth Factor; Purines; Randomized Controlled Trials as Topic; Rats; Sheep; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2007 |
Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Cardiac Catheterization; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Male; Middle Aged; Piperazines; Purines; Retreatment; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents | 2007 |
Results of European post-marketing surveillance of bosentan in pulmonary hypertension.
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Bosentan; Europe; Humans; Hypertension, Pulmonary; Internet; Product Surveillance, Postmarketing; Prospective Studies; Sulfonamides | 2007 |
[Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Eisenmenger Complex; Female; Humans; Hypertension, Pulmonary; Infant; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
[An initial experience of endotherine-1 dual-receptor blockade in the treatment of sustained pulmonary hypertension early after congenital cardiac surgery in infancy].
Topics: Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Female; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Infant; Postoperative Complications; Sulfonamides | 2007 |
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Exercise Tolerance; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Oxygen; Safety; Sulfonamides | 2007 |
Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Bosentan; Catheterization; Disease-Free Survival; Female; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Male; Platelet Aggregation Inhibitors; Proportional Hazards Models; Sulfonamides; Treatment Outcome | 2007 |
Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Echocardiography; Follow-Up Studies; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Pulmonary Wedge Pressure; Sulfonamides; Transposition of Great Vessels | 2008 |
Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Platelet Aggregation Inhibitors; Sulfonamides; Vasodilator Agents; Waiting Lists | 2007 |
Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Eisenmenger Complex; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Wedge Pressure; Sulfonamides; Time Factors; Treatment Outcome; Vascular Resistance | 2007 |
Complex multidrug therapy in a patient with pulmonary hypertension before and after orthotopic heart transplantation. A case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cardiomyopathy, Restrictive; Contraindications; Drug Therapy, Combination; Epoprostenol; Heart Failure; Heart Transplantation; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2007 |
Severe pulmonary hypertension due to chronic echinococcal pulmonary emboli treated with targeted pulmonary vascular therapy and hepatic resection.
Topics: Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Echinococcosis, Hepatic; Echinococcosis, Pulmonary; Epoprostenol; Hepatectomy; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Pulmonary Embolism; Sulfonamides; Thoracic Surgery, Video-Assisted; Vena Cava, Inferior | 2007 |
[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Phosphodiesterase Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Mixed Connective Tissue Disease; Natriuretic Peptide, Brain; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
[Bosentan and chronic thromboembolic pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Antinuclear; Antihypertensive Agents; Autoantibodies; Bosentan; Case-Control Studies; CD3 Complex; Cell Adhesion Molecules; Centromere; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Integrin alpha4beta1; L-Selectin; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; T-Lymphocytes | 2008 |
Caring for the orphan's orphan: treatment of patients with portopulmonary hypertension.
Topics: Bosentan; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Patient Care; Sulfonamides; Survival Analysis | 2007 |
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.
Topics: Adult; Aged; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides | 2008 |
Bosentan treatment in an adult with pulmonary hypertension due to patent ductus arteriosus permits surgical repair.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiopulmonary Bypass; Ductus Arteriosus, Patent; Female; Humans; Hypertension, Pulmonary; Sulfonamides | 2007 |
Should right ventricle dilatation during exercise have clinical implications in patients with chronic thromboembolic pulmonary hypertension? Case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Dilatation, Pathologic; Echocardiography, Doppler; Exercise Test; Female; Humans; Hypertension, Pulmonary; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thromboembolism; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bosentan; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides | 2008 |
Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis.
Topics: Adult; Antihypertensive Agents; Bosentan; Dyspnea; Echocardiography; Exercise Test; Female; Humans; Hypertension, Pulmonary; Natriuretic Peptide, Brain; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides | 2008 |
Pulmonary hypertension: basic concepts and practical management.
Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Receptors, Endothelin; Sensitivity and Specificity; Sulfonamides; Survival Analysis; Thiophenes; Treatment Outcome | 2008 |
Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Exercise; Female; Heart Rate; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen Consumption; Phosphodiesterase Inhibitors; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Walking | 2008 |
Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Chi-Square Distribution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Parenteral; Male; Middle Aged; Piperazines; Prostaglandins; Purines; Retrospective Studies; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Sulfones; Treatment Outcome | 2008 |
Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension.
Topics: Adult; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Diseases; Liver Transplantation; Male; Piperazines; Pulmonary Artery; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2008 |
Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Retrospective Studies; Sulfonamides; Treatment Outcome; Vasodilator Agents; Walking | 2008 |
Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
Topics: Bosentan; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2008 |
A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Databases as Topic; Eisenmenger Complex; Endothelins; Exercise Test; Female; Health Status; Health Status Indicators; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Retrospective Studies; Sulfonamides; Systole; Time Factors; Treatment Outcome | 2008 |
Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Drug Therapy, Combination; Dyspnea; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Sulfonamides | 2008 |
Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.
Topics: Antihypertensive Agents; Bosentan; Child; Child, Preschool; Europe; Female; Humans; Hypertension, Pulmonary; Liver; Longitudinal Studies; Male; Product Surveillance, Postmarketing; Sulfonamides; Transaminases | 2008 |
Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Epoprostenol; Exercise; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Sulfonamides; Walking | 2008 |
Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Pulmonary Wedge Pressure; Retrospective Studies; Stroke Volume; Sulfonamides; Time Factors; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Right | 2008 |
Bosentan: a rapidly expanding role in the management of cardio-thoracic diseases.
Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Heart Diseases; Humans; Hypertension, Pulmonary; Respiratory Function Tests; Sulfonamides; Thoracic Diseases | 2008 |
Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats.
Topics: Animals; Bosentan; Chronic Disease; Endothelin Receptor Antagonists; Endothelins; Hemodynamics; Hypertension, Pulmonary; Hypoxia; In Vitro Techniques; Male; Rats; Rats, Wistar; Sulfonamides | 1995 |
Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.
Topics: Animals; Blood Pressure; Bosentan; Heart Rate; Hypertension, Pulmonary; Hypoxia; Male; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 1995 |
Telemetry monitoring of pulmonary arterial pressure in freely moving rats.
Topics: Animals; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bosentan; Cardiac Catheterization; Hypertension, Pulmonary; Male; Monocrotaline; Motor Activity; Organ Size; Pulmonary Artery; Rats; Rats, Wistar; Sulfonamides; Telemetry; Weight Gain | 1996 |
The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Endothelins; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Oxygen; Prostaglandin Endoperoxides, Synthetic; Pulmonary Artery; Sulfonamides; Swine; Thromboxane A2; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Viper Venoms | 1996 |
Endothelin causes portal and pulmonary hypertension in porcine endotoxemic shock.
Topics: Analysis of Variance; Animals; Bosentan; Cyclooxygenase Inhibitors; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endotoxemia; Hemodynamics; Hypertension, Portal; Hypertension, Pulmonary; Indomethacin; Liver Circulation; Portal System; Pulmonary Artery; Pulmonary Circulation; Regional Blood Flow; Shock, Septic; Sulfonamides; Swine; Thromboxane B2; Vascular Resistance | 1997 |
Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan.
Topics: Acid-Base Imbalance; Animals; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Endothelin-1; Female; Hemoglobins; Hypertension, Pulmonary; Lactic Acid; Male; Oxygen Consumption; Shock, Septic; Sulfonamides; Swine; Treatment Outcome; Tumor Necrosis Factor-alpha | 1997 |
The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock.
Topics: Animals; Bosentan; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Endothelin Receptor Antagonists; Escherichia coli Infections; Hemodynamics; Hypertension, Pulmonary; Renal Circulation; Shock, Septic; Sulfonamides; Swine | 1997 |
Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Monocrotaline; Neovascularization, Pathologic; Organ Size; Poisons; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; Sulfonamides | 1997 |
Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin.
Topics: Acute Disease; Animals; Antihypertensive Agents; Bosentan; Cardiopulmonary Bypass; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Sulfonamides; Swine | 1999 |
Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Bosentan; Cardiopulmonary Bypass; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Hypoxia; Nitric Oxide; Oxygen; Pulmonary Artery; Receptor, Endothelin A; Receptors, Endothelin; Sulfonamides; Swine; Vascular Resistance | 1999 |
Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Bosentan; Chronic Disease; Culture Techniques; Disease Models, Animal; Dogs; Endothelin-1; Female; Hemodynamics; Hypertension, Pulmonary; Immunohistochemistry; Lung; Male; Probability; Pulmonary Artery; Pulmonary Circulation; Pulmonary Embolism; Reference Values; Sulfonamides; Tomography, Emission-Computed; Vascular Resistance | 2000 |
A new era in the treatment of primary pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Epoprostenol; Female; Genetic Therapy; Humans; Hypertension, Pulmonary; Nitric Oxide; Sulfonamides; Thromboxanes; Vasodilator Agents | 2001 |
Report From the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
Topics: Antihypertensive Agents; Bosentan; Drug Approval; Humans; Hypertension, Pulmonary; Sulfonamides | 2001 |
Improvement of respiratory function by bosentan during endotoxic shock in the pig.
Topics: Animals; Antihypertensive Agents; Bosentan; Enzyme Inhibitors; Female; Hypertension, Pulmonary; Lipopolysaccharides; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pulmonary Edema; Respiration; Shock, Septic; Sulfonamides; Swine; Time Factors | 2001 |
Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
Topics: Antihypertensive Agents; Bosentan; Contraindications; Drug Approval; Drug Interactions; Drug Monitoring; Endpoint Determination; Epoprostenol; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; United States; Vasodilator Agents | 2001 |
Endothelin-receptor antagonists in pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides | 2001 |
[Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides | 2001 |
[Physical endurance improves markedly. New therapy approach in pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Exercise Test; Humans; Hypertension, Pulmonary; Sulfonamides | 2002 |
Treatment of primary pulmonary hypertension -- the next generation.
Topics: Antihypertensive Agents; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Mutation; Protein Serine-Threonine Kinases; Receptors, Transforming Growth Factor beta; Sulfonamides; Vasodilator Agents | 2002 |
Bosentan enters market with risk management program.
Topics: Antihypertensive Agents; Bosentan; Drug Approval; Drug Industry; Humans; Hypertension, Pulmonary; Liver Function Tests; Pregnancy Tests; Product Surveillance, Postmarketing; Risk Management; Sulfonamides; United States; United States Food and Drug Administration | 2002 |
Tracleer. Tablets ease symptoms of rare lung disorder.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides; United States | 2002 |
[Bosentan in pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Drug Interactions; Humans; Hypertension, Pulmonary; Sulfonamides | 2002 |
Bosentan (Tracleer) for pulmonary arterial hypertension.
Topics: Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Fees, Pharmaceutical; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides | 2002 |
Pulmonary hypertension and HIV.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; HIV Infections; Humans; Hypertension, Pulmonary; Sulfonamides | 2002 |
Ease symptoms of pulmonary hypertension with bosentan.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Sulfonamides | 2002 |